[
    {
        "src_smiles": "c1ccc(-c2cc(NCc3cccnc3)n3nccc3n2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a benzene ring substituted with a complex substituent involving a diazole ring system connected via a piperazine-like linker. The structure includes multiple nitrogen atoms which may participate in hydrogen bonding and \u03c0-\u03c0 interactions.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibition likely through interactions with the kinase's active site, facilitated by its nitrogen-rich heterocycles which can form hydrogen bonds and engage in hydrophobic interactions.",
            "Limitation in Source Molecule for Property": "The current structure may have suboptimal binding affinity and selectivity towards GSK3-beta due to limited functional groups available for key interactions. Additionally, solubility and metabolic stability might be inadequate for effective therapeutic application.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors or acceptors to enhance binding affinity. Modify the linker to improve conformational flexibility and reach within the binding pocket. Incorporate electron-withdrawing or donating groups to optimize interactions with amino acid residues. Enhance solubility by adding polar functional groups.",
            "Final Target Molecule": "c1ccc(-c2cc(NC(C)C3cccnc3)n3nccc3n2)cc1"
        }
    },
    {
        "src_smiles": "O=c1cc(Br)c2cccc([N+](=O)[O-])c2[nH]1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a fused heterocyclic compound containing a brominated benzene ring and a nitro-substituted pyrazole moiety. The presence of the bromine atom and the nitro group suggests potential sites for electronic and steric interactions. The molecule has a planar structure, which may facilitate \u03c0-\u03c0 stacking interactions with the target protein.",
            "Property Analysis": "GSK3-beta inhibitors typically require specific interactions within the ATP-binding pocket, including hydrogen bonds and hydrophobic interactions. Key features often include heterocycles that can engage in hydrogen bonding, suitable lipophilicity for membrane permeability, and functional groups that enhance binding affinity through specific interactions.",
            "Limitation in Source Molecule for Property": "The source molecule lacks functional groups that can form strong hydrogen bonds with key residues in the GSK3-beta active site. Additionally, the nitro group may reduce the molecule's overall electron density, potentially decreasing binding affinity. The presence of the bromine atom, while useful for halogen bonding, may also limit the molecule's flexibility and increase molecular weight, potentially affecting bioavailability.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors or acceptors to enhance interactions with the GSK3-beta active site. Replace or modify the nitro group to a more electron-donating substituent to increase binding affinity. Consider reducing steric bulk around the bromine atom or substituting it with a different halogen to optimize halogen bonding. Incorporate a heterocyclic moiety that can better engage with the kinase's binding pocket, potentially increasing selectivity and potency.",
            "Final Target Molecule": "O=C1cc(F)c2cccc([NH](=O)O)c2[nH]1"
        }
    },
    {
        "src_smiles": "O=C(O)c1ccccc1Nc1ccnc(N2CCCCC2)n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, O=C(O)c1ccccc1Nc1ccnc(N2CCCCC2)n1, consists of a benzoic acid moiety connected to a multi-ring system containing a pyridine ring substituted with a piperidine group. The presence of the carboxylic acid group facilitates hydrogen bonding, while the rigid aromatic structures provide a planar framework that may interact with the GSK3-beta active site.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against GSK3-beta due to its ability to form hydrogen bonds and hydrophobic interactions within the kinase's ATP-binding pocket. The piperidine moiety may enhance binding affinity through hydrophobic contacts, and the overall molecular conformation could complement the enzyme's active site architecture.",
            "Limitation in Source Molecule for Property": "The current structure may have suboptimal binding affinity and selectivity for GSK3-beta. The carboxylic acid group, while useful for hydrogen bonding, might decrease cell permeability and metabolic stability. Additionally, the piperidine ring could limit conformational flexibility, potentially hindering optimal interactions within the enzyme's active site.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications can be made to improve binding affinity and selectivity. Replacing the carboxylic acid with bioisosteres such as amides or tetrazoles could increase metabolic stability and cell permeability. Introducing heteroatoms or substituents on the aromatic rings may enhance specific interactions with the kinase. Additionally, adjusting the piperidine ring to a more flexible aliphatic chain could allow better accommodation within the active site.",
            "Final Target Molecule": "O=C(N)Cc1ccccc1Nc1ccnc(N2CCOCC2)n1"
        }
    },
    {
        "src_smiles": "COc1cc2ncnc(N(C)c3ccc(C)c(Cl)c3)c2cc1OC",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a methoxy-substituted benzopyrazole core. It features a fused benzene and pyrazole ring system with methoxy groups at the 1 and 8 positions. The pyrazole ring is N-methylated and further substituted with a 3-chlorobenzyl group, enhancing its aromatic character and potential for \u03c0-\u03c0 stacking interactions.",
            "Property Analysis": "The molecule exhibits structural features beneficial for GSK3-beta inhibition, such as a planar aromatic system that may facilitate binding to the kinase's active site. The presence of electron-donating and electron-withdrawing groups can modulate electronic properties, potentially enhancing binding affinity and specificity through hydrogen bonding and hydrophobic interactions.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal hydrogen bonding capacity and specific functional groups necessary for high-affinity binding to GSK3-beta. Additionally, the steric bulk of the 3-chlorobenzyl substituent might hinder the molecule from fitting efficiently into the kinase's active site, potentially limiting its inhibitory potency.",
            "Optimization for Source Molecule": "Modify the substituents to enhance hydrogen bonding capabilities and reduce steric hindrance. Introduce a hydrogen bond acceptor or donor to interact more effectively with amino acid residues in GSK3-beta's active site. Replace the bulky 3-chlorobenzyl group with a smaller substituent to improve binding efficiency. Additionally, consider adding fluorine atoms to increase metabolic stability and binding affinity through electronic effects.",
            "Final Target Molecule": "COc1cc2ncnc(N(C)c3ccc(CF)c(Cl)c3)c2cc1OC"
        }
    },
    {
        "src_smiles": "COc1ccc(-c2cc3c(NCc4ccccc4)ncnc3o2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a methoxy-substituted phenyl ring connected to a fused bicyclic system containing a triazole and pyridine moieties. Additionally, there is a secondary amine linked to a phenyl ring, forming a complex aromatic structure.",
            "Property Analysis": "The molecule exhibits potential inhibition of Glycogen Synthase Kinase 3-beta (GSK3-beta) due to its aromatic and heterocyclic components, which may facilitate interactions with the kinase's active site. However, the current structure may lack optimal binding affinity and selectivity.",
            "Limitation in Source Molecule for Property": "The molecule may have limited hydrogen bonding capabilities and suboptimal positioning of functional groups necessary for strong and selective binding to GSK3-beta. Additionally, the presence of bulky groups might hinder effective interaction within the kinase's ATP-binding pocket.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors/acceptors to enhance binding affinity. Modify substituents to reduce steric hindrance and improve selectivity towards GSK3-beta. Incorporate a linker that positions key functional groups optimally within the kinase active site, potentially increasing inhibitory potency.",
            "Final Target Molecule": "COc1ccc(-c2cc3c(NCc4ccc(C=O)cc4)ncnc3o2)cc1"
        }
    },
    {
        "src_smiles": "CNc1nn2c(C)cc(CO)nc2c1S(=O)(=O)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a benzimidazole core substituted with a methylamino group at one position and a tosyl (p-toluenesulfonyl) group at another. Additionally, there is a hydroxyethyl side chain attached to the aromatic ring, which may influence the molecule's solubility and binding properties.",
            "Property Analysis": "GSK3-beta inhibition is critical for regulating various cellular processes, including glycogen metabolism and Wnt signaling pathways. Effective inhibitors typically form key hydrogen bonds and hydrophobic interactions within the ATP-binding pocket of GSK3-beta, enhancing selectivity and potency.",
            "Limitation in Source Molecule for Property": "The tosyl group may introduce steric hindrance, potentially limiting optimal binding within the GSK3-beta active site. Additionally, the presence of the hydroxyethyl side chain could reduce lipophilicity, affecting membrane permeability and bioavailability.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the tosyl group can be replaced with a smaller sulfonamide moiety to reduce steric bulk and improve binding efficiency. Introducing a fluorine atom on the aromatic ring could increase lipophilicity and metabolic stability. Modifying the hydroxyethyl side chain to a more lipophilic substituent can further improve membrane permeability and overall bioavailability.",
            "Final Target Molecule": "CNc1nn2c(C)cc(CF)nc2c1S(=O)(=O)N(C)C1=CC=CC=C1"
        }
    },
    {
        "src_smiles": "Nc1nonc1-c1nc2ccccc2n1Cc1ccncc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a central triazole ring connected to multiple aromatic and heteroaromatic rings. It features amino groups and nitrogen-containing heterocycles that may facilitate hydrogen bonding and pi-stacking interactions, which are important for biological activity.",
            "Property Analysis": "The molecule exhibits potential as a GSK3-beta inhibitor due to its ability to interact with the kinase's active site through hydrogen bonds and hydrophobic interactions. However, its current potency and selectivity may be limited.",
            "Limitation in Source Molecule for Property": "The source molecule may lack key functional groups that enhance binding affinity and selectivity for GSK3-beta. Additionally, the presence of multiple nitrogen atoms could lead to off-target interactions and reduced drug-likeness.",
            "Optimization for Source Molecule": "Introduce electron-withdrawing groups to increase binding affinity, add substituents to improve selectivity towards GSK3-beta, and modify the aromatic systems to enhance solubility and metabolic stability. For instance, adding a fluorine atom or a methyl group could enhance interactions within the kinase binding site.",
            "Final Target Molecule": "Nc1nonc1-c1nc2cc(C)c(F)cc2n1Cc1ccncc1F"
        }
    },
    {
        "src_smiles": "CC(C)=Cc1ccc2cc(NC(=O)C3CC3)ncc2c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a vinyl isopropyl group attached to a fused aromatic-heterocyclic system. It contains a nitrogen atom connected to a carbonyl group and a cyclopropyl moiety within the heterocycle, contributing to its overall structural rigidity and lipophilicity.",
            "Property Analysis": "The compound exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta) likely through interactions involving the carbonyl and nitrogen functionalities. The cyclopropyl group and aromatic rings facilitate hydrophobic interactions within the enzyme's active site, enhancing binding affinity.",
            "Limitation in Source Molecule for Property": "The cyclopropyl group introduces significant steric hindrance, potentially limiting optimal binding within the GSK3-beta active site. Additionally, the molecule lacks additional hydrogen bond donors or acceptors that could form stronger interactions with the enzyme, potentially reducing its inhibitory potency.",
            "Optimization for Source Molecule": "Modify the cyclopropyl moiety to a more flexible aliphatic chain, such as a cyclohexyl group, to reduce steric hindrance and enhance conformational flexibility. Introduce a hydroxyl group on the aromatic ring to provide additional hydrogen bonding capability, thereby strengthening interactions with GSK3-beta. These changes aim to improve binding affinity and overall inhibitory activity.",
            "Final Target Molecule": "CC(C)=Cc1ccc2cc(NC(=O)C3CCCCC3)ncc2c1O"
        }
    },
    {
        "src_smiles": "CCc1[nH]c2ccc(OC)cc2c1C1=CCNCC1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a 2-methylindole core substituted with a methoxy group at the 5-position. Additionally, it contains a piperidine ring linked to the indole nitrogen, forming a fused bicyclic structure. The overall structure includes both aromatic and aliphatic components, providing potential sites for interaction with biological targets.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta). The indole core is known for its ability to engage in hydrogen bonding and hydrophobic interactions within the ATP-binding site of kinases. The presence of the methoxy group may enhance binding affinity through additional electronic and steric interactions.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited selectivity towards GSK3-beta over other kinases, potentially leading to off-target effects. Additionally, the piperidine ring might contribute to metabolic instability and reduce the overall drug-like properties of the molecule. There may also be suboptimal binding interactions that limit inhibitory potency.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, the indole core can be further substituted to enhance specific interactions within the kinase active site. Introducing electron-withdrawing groups may increase binding affinity, while modifying the piperidine ring to a more rigid structure could improve selectivity and metabolic stability. Incorporating polar functional groups could also enhance solubility and reduce off-target interactions.",
            "Final Target Molecule": "CCc1nccc(O)c1C1=CCNCC1O"
        }
    },
    {
        "src_smiles": "Cc1ccc(-c2nnc(SCc3ccccc3)o2)c(O)c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a phenolic core substituted with a methyl group at the para position and a thienoimidazole moiety attached via a sulfur-linked thiophenyl group. The presence of the hydroxyl group allows for potential hydrogen bonding interactions, which may contribute to its biological activity.",
            "Property Analysis": "This molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta). The thienoimidazole moiety is crucial for binding to the enzyme's active site, while the phenolic hydroxyl group may facilitate additional interactions that enhance binding affinity and inhibitory potency.",
            "Limitation in Source Molecule for Property": "The source molecule may have limited potency and selectivity towards GSK3-beta due to the presence of a methyl group, which could reduce metabolic stability and hinder optimal binding interactions. Additionally, the thiophene ring may be susceptible to metabolic degradation, potentially decreasing the compound's overall efficacy.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibitory activity, introduce electron-withdrawing groups such as a trifluoromethyl group in place of the methyl substituent to increase binding affinity and metabolic stability. Additionally, modifying the thienoimidazole moiety to incorporate substituents that enhance hydrogen bonding and steric complementarity with the enzyme's active site could improve selectivity and potency.",
            "Final Target Molecule": "C(F)(F)Fc1ccc(-c2nnc(SCc3ccccc3)o2)c(O)c1"
        }
    },
    {
        "src_smiles": "O=C(O)CSc1nonc1-c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule comprises a carboxylic acid moiety connected to a thioether linkage. This thioether is attached to a 1,2,4-oxadiazole ring and a phenyl ring. Key functional groups include the carboxyl group, thioether (\u2013S\u2013), heterocyclic oxadiazole ring, and the aromatic phenyl ring.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity due to the presence of the oxadiazole and phenyl rings, which may facilitate interactions with the kinase's active site. However, the current structure may have suboptimal binding affinity and selectivity.",
            "Limitation in Source Molecule for Property": "The thioether linkage may lack the necessary hydrogen bond donors/acceptors required for strong binding to GSK3-beta. Additionally, the molecule may suffer from limited interactions within the ATP-binding pocket, reducing its inhibitory potency and selectivity.",
            "Optimization for Source Molecule": "Replace the thioether linkage with a more polar or hydrogen bond-capable linker, such as an amide or sulfonamide group, to enhance binding interactions. Introduce electron-withdrawing substituents on the phenyl ring to improve binding affinity and selectivity. Modify the oxadiazole ring to a more favorable heterocycle that better complements the GSK3-beta active site.",
            "Final Target Molecule": "O=C(O)C(=O)Nc1nccs1-c1cc(C(F)(F)F)ccc1"
        }
    },
    {
        "src_smiles": "CN(C)c1ccc(C(=O)NCc2ccccc2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, CN(C)c1ccc(C(=O)NCc2ccccc2)cc1, consists of a dimethylamino group attached to a benzene ring, which is further substituted with an amide linkage connected to a phenyl ethyl group. The molecule features aromatic rings and a carbonyl group, providing potential sites for interactions with biological targets.",
            "Property Analysis": "GSK3-beta inhibition is influenced by the molecule's ability to interact with the kinase's active site. The source molecule shows moderate inhibitory activity due to its structural features that allow hydrogen bonding and hydrophobic interactions required for binding to GSK3-beta.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from limited specificity and suboptimal binding affinity towards GSK3-beta. The presence of the dimethylamino group might introduce metabolic liabilities, and the overall molecular rigidity could hinder optimal interactions within the active site.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibitory activity, introduce additional hydrogen bond donors or acceptors to improve binding affinity. Modify the dimethylamino group to reduce metabolic liabilities, possibly by introducing a heteroatom-containing substituent. Incorporate substituents on the aromatic rings to enhance specificity and optimize interactions within the kinase active site.",
            "Final Target Molecule": "CCN(C)C1=CC=C(C(=O)NCC2=CC=CC=C2)C=C1"
        }
    },
    {
        "src_smiles": "Nc1ccccc1NC(=O)c1ccc(CNc2ncccn2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a primary amine linked to a phenyl ring, connected via a urea moiety to another substituted phenyl ring bearing a morpholine derivative. It features multiple aromatic rings, a urea linkage, and heterocyclic nitrogen atoms, which may facilitate hydrogen bonding and \u03c0-\u03c0 interactions with GSK3-beta.",
            "Property Analysis": "The molecule demonstrates moderate inhibition of GSK3-beta, likely through interactions involving hydrogen bonds and hydrophobic contacts within the kinase's active site. The presence of multiple nitrogen atoms may enhance binding affinity but could also influence selectivity and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties.",
            "Limitation in Source Molecule for Property": "The primary limitations include potential lack of selectivity for GSK3-beta over other kinases due to the conserved nature of kinase active sites. Additionally, the molecule may suffer from suboptimal solubility and bioavailability owing to its multiple aromatic systems and hydrogen bond donors, which could hinder effective cellular uptake and distribution.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce substituents that increase binding specificity by interacting with unique residues in GSK3-beta's active site. Modify the urea linkage to a more rigid or bioisosteric group to improve binding affinity and metabolic stability. Incorporate polar functional groups to enhance solubility and reduce off-target interactions, thereby improving overall pharmacokinetic and pharmacodynamic profiles.",
            "Final Target Molecule": "Nc1ccccc1NC(=O)c1ccc(CNCCn2nc3ccccc3n2)cc1"
        }
    },
    {
        "src_smiles": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule contains a methoxy-substituted triazolo-pyridine core linked to a urea moiety attached to a cyclohexylphenyl group. It features multiple aromatic rings and hydrogen bond donors/acceptors, which are important for kinase inhibition.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta) through hydrogen bonding and hydrophobic interactions within the kinase active site. Its structural features allow for potential strong binding affinity.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited selectivity towards GSK3-beta, potential metabolic instability due to the urea linkage, and suboptimal solubility, which can affect bioavailability and efficacy.",
            "Optimization for Source Molecule": "Enhance selectivity by introducing substituents that better fit the unique pockets of GSK3-beta. Modify the urea linkage to improve metabolic stability, such as replacing it with a bioisostere like a sulfonamide. Improve solubility by adding polar groups or reducing lipophilic regions without compromising binding affinity.",
            "Final Target Molecule": "COc1n[nH]c2cc(NC(=S)NS(C)C(c3ccccc3)C4CCCCC4)c(ncc12)C5=CC=CC=C5"
        }
    },
    {
        "src_smiles": "CCC(C)Nc1ncnc2cc(OC)c(OC)cc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, CCC(C)Nc1ncnc2cc(OC)c(OC)cc12, consists of a butyl chain attached to an aniline moiety connected to a triazole-fused benzene ring with two methoxy groups. The presence of the aniline and triazole rings suggests potential for hydrogen bonding and pi-stacking interactions, while the methoxy groups contribute to electronic modulation and solubility.",
            "Property Analysis": "The molecule exhibits moderate inhibitory activity against GSK3-beta, likely due to interactions between the triazole and aniline moieties with the kinase's active site. The methoxy groups may enhance solubility and electronic distribution, aiding in binding affinity. However, overall potency may be limited by suboptimal binding interactions and selectivity.",
            "Limitation in Source Molecule for Property": "The current scaffold may lack optimal hydrogen bond donors/acceptors necessary for stronger binding to GSK3-beta. Additionally, the molecule may suffer from limited specificity, potentially interacting with other kinases, leading to off-target effects. Solubility and metabolic stability could also be areas of concern.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors to enhance binding affinity and specificity for GSK3-beta. Modify the butyl chain to a more rigid linker to improve binding orientation. Replace one of the methoxy groups with a bioisostere to increase metabolic stability. Enhance aromatic interactions by adding fluorine substituents to the benzene ring.",
            "Final Target Molecule": "CC(C)NC1ncnc2cc(OC)c(F)c(F)cc12"
        }
    },
    {
        "src_smiles": "COC(=O)CSc1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule comprises a methyl ester group (COC(=O)) connected via a thioether linkage (CS) to a five-membered heterocyclic ring containing two nitrogen atoms. The ring is substituted with a fluorophenyl group and a pyridinyl group, which may contribute to its interaction with the GSK3-beta enzyme.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity through its heterocyclic structure, which can facilitate hydrogen bonding and pi-stacking interactions within the enzyme's active site. The fluorine atom on the phenyl ring may enhance metabolic stability and binding affinity.",
            "Limitation in Source Molecule for Property": "The current structure may lack sufficient hydrogen bond donors or acceptors to form robust interactions with key residues in the GSK3-beta active site. Additionally, the thioether linkage may introduce flexibility that reduces binding specificity and affinity.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond acceptor groups to enhance interactions with the enzyme. Replace the thioether linkage with a more rigid carbon linker to improve binding orientation and specificity. Modify the phenyl rings by adding electron-withdrawing groups to increase binding affinity and metabolic stability.",
            "Final Target Molecule": "COC(=O)CC1NC(-c2c(F)cc(F)c2)C(=O)Nc2ccncc2)N1"
        }
    },
    {
        "src_smiles": "Cc1cccc2[nH]c(-c3ccccn3)nc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, represented by the SMILES string Cc1cccc2[nH]c(-c3ccccn3)nc12, consists of a fused bicyclic structure. It features a methyl-substituted benzene ring connected to a bicyclic pyrimidine-like ring system, which includes a nitrogen-containing heterocycle with an amine (-NH) group.",
            "Property Analysis": "The source molecule demonstrates moderate inhibition of Glycogen Synthase Kinase 3-beta (GSK3-beta), making it a viable lead compound for further optimization in the development of more potent inhibitors.",
            "Limitation in Source Molecule for Property": "The primary limitations include limited binding affinity to the GSK3-beta active site and potential metabolic instability due to the methyl group, which may hinder the molecule's overall effectiveness and pharmacokinetic properties.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications could include introducing electron-withdrawing groups to strengthen hydrogen bonding interactions within the active site, replacing the methyl group with a more metabolically stable moiety to improve pharmacokinetics, and adding substituents that enhance specificity and binding affinity.",
            "Final Target Molecule": "Cc1ccc2[nH]c(-c3ccccn3)nc(C(F)(F)F)12"
        }
    },
    {
        "src_smiles": "CN1CCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)CC1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule comprises a piperidine ring linked to a fused aromatic system containing a thiazole ring and an amidine functional group. The presence of nitrogen atoms in both the piperidine and thiazole rings suggests potential hydrogen bonding capabilities essential for GSK3-beta inhibition.",
            "Property Analysis": "The molecule exhibits moderate inhibitory activity against GSK3-beta, likely due to its ability to form key hydrogen bonds and hydrophobic interactions within the enzyme's active site. The thiazole and amidine groups contribute to its binding affinity.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from suboptimal selectivity and potency. The amidine group could lead to off-target interactions, and the rigid piperidine ring limits conformational flexibility, potentially reducing binding efficiency.",
            "Optimization for Source Molecule": "Introduce substituents on the thiazole ring to enhance hydrophobic interactions and selectivity for GSK3-beta. Modify the amidine group to improve water solubility and reduce off-target binding. Incorporate a flexible linker to allow better conformational adaptability within the enzyme's active site.",
            "Final Target Molecule": "CN1CCCOC(c2c[nH]c3ccc(N=C(NC)C)c4cccs4)cc23)CC1"
        }
    },
    {
        "src_smiles": "COc1cc(OC)c(-c2ccnc(N)n2)c(OC)c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, represented by the SMILES string COc1cc(OC)c(-c2ccnc(N)n2)c(OC)c1, consists of a benzene ring substituted with three methoxy groups and a pyrimidin-2-amine moiety. The methoxy groups enhance electron density and solubility, while the pyrimidine ring provides potential hydrogen bonding sites crucial for kinase inhibition.",
            "Property Analysis": "Glycogen Synthase Kinase 3-beta (GSK3-beta) inhibitors typically require interactions with the ATP-binding pocket, involving hydrogen bonds with key residues and hydrophobic interactions to ensure specificity and potency. Effective inhibitors often possess heterocyclic rings and functional groups that can form stable interactions within the active site.",
            "Limitation in Source Molecule for Property": "The source molecule may lack optimal functional groups necessary for strong hydrogen bonding with GSK3-beta's active site residues. Additionally, the rigid structure might not sufficiently occupy the hydrophobic regions of the ATP-binding pocket, potentially resulting in lower binding affinity and specificity.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce functional groups that can form additional hydrogen bonds, such as amino or hydroxyl groups. Incorporating a heterocyclic ring adjacent to the methoxy-substituted benzene can increase hydrophobic interactions and improve fit within the ATP-binding pocket. Modifying the existing substituents to optimize electronic properties and reduce steric hindrance may also enhance binding affinity.",
            "Final Target Molecule": "COc1cc(OC)c(Nc2ccncn2)c(OC)c1N"
        }
    },
    {
        "src_smiles": "COc1cc2ncnc(NC(C)C)c2cc1OC",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a 1,4-dimethoxy-substituted triazole derivative. It consists of two methoxy groups attached to an aromatic ring, which is fused to a triazole ring. The triazole is further substituted with a dimethylamino group, enhancing its electron-donating properties and potential interactions with biological targets.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta). Its structure allows for interactions within the kinase's ATP-binding pocket, potentially forming hydrogen bonds and hydrophobic interactions essential for effective inhibition.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from limited binding affinity and selectivity towards GSK3-beta due to suboptimal positioning of functional groups for key interactions. Additionally, metabolic stability and solubility issues might hinder its effectiveness as a potent inhibitor.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce a hydroxyl group to increase hydrogen bonding capabilities and improve binding affinity. Replace one of the methoxy groups with a fluorine atom to enhance hydrophobic interactions and metabolic stability. Additionally, modify the dimethylamino group to a more flexible amine to improve selectivity and binding conformation within the ATP-binding site.",
            "Final Target Molecule": "COc1cc(F)c2ncnc(NC(C)C)c2cc1O"
        }
    },
    {
        "src_smiles": "Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, represented by the SMILES string Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1, contains a central pyridine ring substituted with two amino groups. One amino group is directly attached to the pyridine, while the other is connected to a substituted phenyl ether. The molecule features multiple aromatic rings, a chlorine substituent, and ether linkages, which may contribute to its binding interactions and overall stability.",
            "Property Analysis": "The molecule is designed to inhibit Glycogen Synthase Kinase 3-beta (GSK3-beta) by interacting with its active site. The presence of amino groups facilitates hydrogen bonding with amino acid residues in the kinase, while the aromatic rings enable \u03c0-\u03c0 stacking interactions. The chlorine-substituted phenyl ether may enhance lipophilicity, potentially improving cellular permeability and binding affinity.",
            "Limitation in Source Molecule for Property": "Despite its potential, the source molecule may exhibit limited selectivity towards GSK3-beta over other kinases due to its relatively simple structure. Additionally, the molecule's polar amino groups could reduce its membrane permeability, potentially affecting its bioavailability. The existing substituents may not fully engage the key interaction hotspots within the GSK3-beta active site, leading to suboptimal inhibitory activity.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the molecule can be optimized by introducing substituents that increase binding specificity and affinity. Adding bulkier or more electron-withdrawing groups to the aromatic rings may strengthen interactions with the kinase's active site. Reducing the number of amino groups or modifying them to tertiary amines could improve selectivity and membrane permeability. Incorporating heteroatoms or linker modifications might also facilitate better orientation and binding within the enzyme's active pocket.",
            "Final Target Molecule": "Nc1ccnc(NC2=CC=C(Oc3ccc(Cl)cc3)C=C2)c1C"
        }
    },
    {
        "src_smiles": "c1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central pyrimidine ring substituted at the 2-position with a phenyl group and at the 4-position with a benzene ring. This arrangement allows for planar stacking interactions and potential hydrogen bonding, which are favorable for kinase inhibition.",
            "Property Analysis": "The molecule exhibits foundational activity as a GSK3-beta inhibitor, likely due to the pyrimidine core facilitating interactions with the kinase's ATP-binding site. However, the current configuration may lack optimal binding affinity and selectivity.",
            "Limitation in Source Molecule for Property": "The existing structure may suffer from limited hydrophobic interactions and suboptimal positioning of functional groups necessary for maximal inhibition of GSK3-beta. Additionally, the absence of electron-donating or withdrawing groups could reduce binding efficacy and selectivity.",
            "Optimization for Source Molecule": "Introduce electron-donating substituents on the phenyl rings to enhance binding interactions. Modify the pyrimidine core by adding a methyl group at the 5-position to increase hydrophobic contacts. Additionally, incorporate a hydroxyl group to facilitate hydrogen bonding with key residues in GSK3-beta.",
            "Final Target Molecule": "c1ccc(-c2c[nH]c(C)nc2c3ccc(cc3)O)cc1"
        }
    },
    {
        "src_smiles": "c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a fused tricyclic heterocycle comprising multiple nitrogen atoms, forming a complex ring system that facilitates hydrogen bonding and \u03c0-\u03c0 stacking interactions. This structure provides a versatile scaffold for interacting with biological targets.",
            "Property Analysis": "The molecule demonstrates moderate inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta). Its heterocyclic framework allows for potential interactions within the active site of GSK3-beta, contributing to its inhibitory properties.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from suboptimal binding affinity and selectivity towards GSK3-beta. Additionally, the lack of specific functional groups could limit the formation of strong hydrogen bonds and hydrophobic interactions necessary for enhanced inhibition.",
            "Optimization for Source Molecule": "Introduce electron-withdrawing substituents, such as a fluorine atom, to enhance binding affinity through increased hydrogen bonding with key residues in GSK3-beta. Modify the ring system to improve lipophilicity and selectivity, thereby enhancing overall inhibitory potency.",
            "Final Target Molecule": "c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23F)cn1"
        }
    },
    {
        "src_smiles": "CC(C)n1cnc2c(NCc3ccccc3)ncnc21",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule CC(C)n1cnc2c(NCc3ccccc3)ncnc21 consists of a bicyclic structure containing fused pyrimidine and triazine rings. It features an isopropyl group attached to the nitrogen atom of the triazine ring and a phenethyl substituent linked via a carbon bridge to the inner nitrogen of the pyrimidine ring. The overall structure provides multiple nitrogen atoms that can act as hydrogen bond donors or acceptors, contributing to potential binding interactions.",
            "Property Analysis": "GSK3-beta (Glycogen Synthase Kinase 3-beta) is a serine/threonine kinase involved in various cellular processes. Effective inhibition of GSK3-beta requires molecules that can interact specifically with its ATP-binding pocket and substrate interaction sites. The current molecule offers a tricyclic framework that could facilitate binding through hydrogen bonds and hydrophobic interactions. However, the existing substituents may not provide optimal interactions necessary for high-affinity inhibition.",
            "Limitation in Source Molecule for Property": "The primary limitation of the source molecule is the lack of specific functional groups that can form strong and selective interactions with key residues in the GSK3-beta active site. The isopropyl group may contribute to hydrophobic interactions but lacks the necessary hydrogen bond donors/acceptors to enhance binding affinity. Additionally, the phenethyl substituent might introduce rigidity, limiting the molecule's ability to adapt to the enzyme's binding pocket for optimal inhibition.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, the molecule can be optimized by introducing polar functional groups to enhance hydrogen bonding with the kinase's active site. Modifying the isopropyl group to a more rigid or extended alkyl chain could improve hydrophobic interactions. Additionally, replacing the phenethyl substituent with a heteroaromatic ring containing nitrogen or oxygen atoms may increase binding specificity and affinity. Introducing a methoxy or hydroxyl group on the phenyl ring can provide additional hydrogen bonding opportunities.",
            "Final Target Molecule": "CC(C)n1cnc2c(NCc3cc(ccc3O)C)ncnc21"
        }
    },
    {
        "src_smiles": "COc1ccc(SC)cc1CNC1CCCNC1c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a methoxy-substituted benzene ring connected via a thioether linkage to a piperazine ring, which is further linked to a second phenyl group. This structure includes aromatic systems, ether and thioether functionalities, and a flexible piperazine moiety that may participate in hydrogen bonding.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity through its ability to engage in hydrogen bonding and hydrophobic interactions within the active site of the kinase. The presence of multiple aromatic rings may facilitate \u03c0-\u03c0 stacking interactions, enhancing binding affinity. The piperazine ring provides essential flexibility and potential for interactions with amino acid residues in the target enzyme.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited selectivity towards GSK3-beta due to the presence of multiple aromatic rings, which can lead to off-target interactions. Additionally, the thioether linkage might reduce metabolic stability, and the molecule may lack optimal positioning of hydrogen bond donors/acceptors required for strong binding affinity.",
            "Optimization for Source Molecule": "Introduce electron-withdrawing groups on the aromatic rings to enhance binding affinity through stronger interactions with the kinase. Replace the thioether linkage with a more metabolically stable amide or triazole linker to improve stability. Modify the piperazine ring by adding substituents that can form additional hydrogen bonds or ionic interactions with GSK3-beta, thereby increasing selectivity and potency.",
            "Final Target Molecule": "COc1ccc(SC(=O)N)cc1CNC1CCN(CC1)c1c(C=O)ccc(C)c1"
        }
    },
    {
        "src_smiles": "c1ccc(Cn2cc(CSc3nnc(C4CCCC4)o3)nn2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, represented by the SMILES string c1ccc(Cn2cc(CSc3nnc(C4CCCC4)o3)nn2)cc1, consists of a benzene ring substituted with a pyrimidine fused to a thiazole and oxazole ring system. It features multiple nitrogen and sulfur heteroatoms, a piperidine-like cyclohexane ring, and thioether linkages. The molecule's intricate fused ring system may facilitate specific interactions with biological targets through hydrogen bonding and hydrophobic interactions.",
            "Property Analysis": "GSK3-beta inhibitors typically require a combination of hydrogen bond donors/acceptors and hydrophobic regions to interact effectively with the kinase's ATP-binding pocket. Key features often include planar aromatic systems for stacking interactions, appropriate molecular rigidity to fit the binding site, and functional groups that can form specific interactions with amino acid residues such as lysine, valine, or glycine. Additionally, favorable pharmacokinetic properties like solubility and metabolic stability are essential for efficacy.",
            "Limitation in Source Molecule for Property": "The source molecule may exhibit limited hydrophobic surface area necessary for optimal binding within the GSK3-beta active site. The presence of multiple heteroatoms could lead to increased polarity, potentially reducing membrane permeability and bioavailability. Additionally, the current structure might lack specific functional groups required for strong hydrogen bonding with key residues in the kinase, potentially diminishing inhibitory potency.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the molecule can be optimized by increasing hydrophobic character through the introduction of alkyl or aromatic substituents, thereby improving binding affinity within the hydrophobic pockets of the kinase. Modifying the heteroaryl system to include electron-donating or withdrawing groups can strengthen hydrogen bond interactions with active site residues. Reducing excessive polarity by replacing certain heteroatoms or introducing bioisosteres can improve membrane permeability and metabolic stability. Additionally, increasing molecular rigidity may enhance specificity and binding affinity.",
            "Final Target Molecule": "c1ccc(CCn2cc(COc3nnc(C4CCCC4)O3)nn2)cc1"
        }
    },
    {
        "src_smiles": "Cc1cc2[nH]ncc2cc1-c1ccccc1C(F)(F)F",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a biphenyl core where a methyl-substituted pyrazole ring is connected to a phenyl ring bearing a trifluoromethyl group. The presence of the trifluoromethyl group may enhance the molecule's lipophilicity and metabolic stability.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity due to the presence of the pyrazole moiety, which is known to interact with kinase active sites. The trifluoromethyl group may contribute to binding affinity and specificity.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding interactions within the GSK3-beta active site, possibly due to limited hydrogen bonding capabilities and insufficient interactions with key amino acid residues.",
            "Optimization for Source Molecule": "Introduce polar functional groups such as hydroxyl or amine substituents to enhance hydrogen bonding with the kinase active site. Additionally, modifying the biphenyl linker to include a flexible linker may improve binding orientation and affinity. Reducing steric hindrance around the trifluoromethyl group could also facilitate better binding interactions.",
            "Final Target Molecule": "Cc1cc2ncc(n2cc1O)cc3ccccc3C(F)(F)F"
        }
    },
    {
        "src_smiles": "c1ccc2c(N3CCCCCC3)nc(-c3ccncc3)nc2c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a fused bicyclic structure with a triazole ring connected to a piperazine moiety and a 2-aminopyridine group. The molecule contains aromatic rings that may facilitate \u03c0-\u03c0 interactions.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity through interactions of the triazole and pyridine rings with the kinase active site. The piperazine moiety may enhance solubility and cellular permeability.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal binding interactions within the GSK3-beta active site, potentially leading to moderate affinity and selectivity. Additionally, the flexibility of the piperazine ring might reduce binding specificity.",
            "Optimization for Source Molecule": "Introduce a hydrogen bond donor/acceptor to enhance binding affinity, add a halogen substituent to improve selectivity, and rigidify the linker to reduce conformational flexibility, thereby increasing target specificity.",
            "Final Target Molecule": "c1ccc2c(N3CCN(CC3)C)nc(-c3ccncc3Cl)nc2c1"
        }
    },
    {
        "src_smiles": "COc1ccc(-c2nnc(SCC#N)o2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, COc1ccc(-c2nnc(SCC#N)o2)cc1, comprises a benzene ring substituted with a methoxy group (CO-) and a pyrimidine derivative. The pyrimidine ring is further functionalized with a thioethyl nitrile group (SCC#N) and a hydroxyl group. This structure combines aromatic and heteroaromatic systems, which may contribute to its biological activity through potential interactions with enzyme active sites.",
            "Property Analysis": "The molecule exhibits features that are favorable for GSK3-beta inhibition, such as the presence of the pyrimidine ring, which is known to interact with kinase enzymes. The thioethyl nitrile moiety may enhance binding affinity through hydrogen bonding and electronic interactions. Additionally, the methoxy-substituted benzene ring can contribute to the molecule's overall lipophilicity, potentially improving membrane permeability and cellular uptake.",
            "Limitation in Source Molecule for Property": "The current structure may have suboptimal binding affinity and selectivity for GSK3-beta due to the electron-donating nature of the methoxy group, which could affect the electronic distribution necessary for optimal enzyme interaction. Furthermore, the thioethyl nitrile group may pose metabolic stability issues, potentially leading to rapid degradation and reduced bioavailability.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the methoxy group can be replaced with an electron-withdrawing substituent to improve electronic compatibility with the enzyme's active site. Additionally, modifying the thioethyl nitrile group to a more metabolically stable moiety, such as a fluorinated group, could enhance the compound's pharmacokinetic properties. Introducing a bulky substituent near the pyrimidine ring may also increase selectivity by improving specific interactions within the GSK3-beta binding pocket.",
            "Final Target Molecule": "Clc1ccc(-c2nnc(SC(F)C#N)o2)cc1"
        }
    },
    {
        "src_smiles": "Cn1ccc(Oc2ccc3cc(NC(=O)C4CC4)ncc3c2)n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, Cn1ccc(Oc2ccc3cc(NC(=O)C4CC4)ncc3c2)n1, features a methoxy-substituted aromatic ring connected via an ether linkage to a fused aromatic and pyridine-like system. The structure includes a cyclic amide moiety (NC(=O)C4CC4), which may contribute to hydrogen bonding and rigidity. The presence of nitrogen atoms and the ether linkage suggests potential sites for interaction with the GSK3-beta active site.",
            "Property Analysis": "The molecule demonstrates features that are favorable for kinase inhibition, such as aromatic rings for \u03c0-\u03c0 stacking interactions, hydrogen bond donors/acceptors for binding, and a rigid framework that may enhance binding specificity. However, the overall polarity and molecular size may affect cell permeability and bioavailability. Additionally, the current substituents may not optimally interact with all key residues in the GSK3-beta binding pocket.",
            "Limitation in Source Molecule for Property": "The source molecule may lack specific functional groups that enhance binding affinity and selectivity towards GSK3-beta. The methoxy groups could be insufficient for forming strong hydrogen bonds, and the cyclic amide may not engage effectively with the kinase\u2019s active site residues. The molecule\u2019s flexibility might also limit optimal positioning within the binding pocket.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, introduce electron-withdrawing groups to enhance binding interactions, incorporate additional hydrogen bond donors or acceptors to form stronger interactions with the kinase, and increase rigidity by adding cycloalkyl or aromatic substituents to better fit the binding pocket. Modifying the cyclic amide to a more constrained or bioisosteric group could also enhance selectivity and potency.",
            "Final Target Molecule": "Cn1ccc(Oc2ccc3cc(NC(=O)C4C[C@H]4)ncc3c2)n1"
        }
    },
    {
        "src_smiles": "OCc1cccc(Nc2nc(-c3cccnc3)nc3ccccc23)c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central phenyl ring substituted with a hydroxyl group (OCc1cccc) and connected to a nitrogen-containing heterocyclic system. This system includes a triazole moiety (-c3cccnc3) fused to a piperazine-like structure (Nc2nc(-c3cccnc3)nc3ccccc23). The molecule exhibits multiple aromatic rings and nitrogen atoms, which may facilitate hydrogen bonding and pi-stacking interactions crucial for GSK3-beta inhibition.",
            "Property Analysis": "The molecule acts as an inhibitor of Glycogen Synthase Kinase 3-beta (GSK3-beta), an enzyme involved in various cellular processes including metabolism, cell cycle regulation, and neuronal function. Inhibition of GSK3-beta has therapeutic potential in treating diseases such as Alzheimer's, bipolar disorder, and certain cancers.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from suboptimal potency and selectivity towards GSK3-beta. Additionally, the presence of multiple aromatic rings could lead to poor solubility and bioavailability. Metabolic stability might be an issue due to possible sites of metabolic oxidation, and the rigid structure may limit the molecule's ability to adapt to the binding site, affecting efficacy.",
            "Optimization for Source Molecule": "Enhance potency and selectivity by introducing electron-withdrawing groups on the phenyl ring to strengthen binding interactions. Modify the triazole moiety to a more metabolically stable bioisostere to improve metabolic stability. Reduce the number of aromatic rings or introduce flexible linkers to enhance solubility and bioavailability. Incorporate substituents that can form additional hydrogen bonds or hydrophobic interactions within the GSK3-beta active site to increase binding affinity.",
            "Final Target Molecule": "CC(=O)c1ccc(cc1)Nc2ncc3cccnc3nc2c4ccccc4"
        }
    },
    {
        "src_smiles": "Cn1nc(C(N)=O)c2c1-c1nc(NCc3ccccc3)ncc1CC2",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule contains a fused heterocyclic system with imidazole and thiazole rings connected via a piperidine linker. It includes an amidine moiety and a phenyl substitution, which may contribute to its biological activity.",
            "Property Analysis": "The molecule exhibits inhibitory activity against GSK3-beta, potentially through interactions with the enzyme's active site. Key functional groups such as the amidine and phenyl rings may play crucial roles in binding affinity and specificity.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited binding interactions and suboptimal pharmacokinetic properties, such as solubility and cell permeability, which can affect its overall inhibitory potency and selectivity towards GSK3-beta.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors or acceptors to enhance binding interactions with GSK3-beta. Modify the phenyl ring to include electron-donating or withdrawing groups to improve binding affinity. Additionally, optimize the piperidine linker to increase conformational flexibility and improve pharmacokinetic properties.",
            "Final Target Molecule": "Cn1nc(C(N)=O)c2c1-c1nc(NCc3cc(O)ccc3)ncc1CC2"
        }
    },
    {
        "src_smiles": "Cc1sc2ncnc(NCCCO)c2c1C",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule Cc1sc2ncnc(NCCCO)c2c1C is a methyl-substituted thiazole fused with a pyrazole ring. It contains a sulfur atom in the thiazole ring, a nitrogen-containing pyrazole ring, and an amino chain with a hydroxyethyl moiety.",
            "Property Analysis": "GSK3-beta inhibitors typically require appropriate binding affinity to the kinase's ATP-binding pocket. Key interactions often involve hydrogen bonding, hydrophobic interactions, and sometimes pi-stacking with conserved residues in GSK3-beta. The source molecule has potential sites for hydrogen bonding and hydrophobic interactions but may lack optimal binding affinity and selectivity.",
            "Limitation in Source Molecule for Property": "The current structure may exhibit limited specificity towards GSK3-beta due to insufficient interactions within the ATP-binding site. Additionally, the molecule might have suboptimal pharmacokinetic properties, such as poor cell permeability or metabolic stability, reducing its efficacy as a GSK3-beta inhibitor.",
            "Optimization for Source Molecule": "Introduce substituents that enhance hydrogen bonding and hydrophobic interactions within the GSK3-beta binding pocket. Modify the amino chain to improve binding affinity and selectivity, possibly by adding aromatic groups for pi-stacking or polar groups to form additional hydrogen bonds. Optimize the molecule's pharmacokinetic properties by enhancing solubility and metabolic stability through structural modifications.",
            "Final Target Molecule": "CC1=CSC2=NCN=C(NCCc3ccccc3O)C=C12"
        }
    },
    {
        "src_smiles": "CCNc1nc2cc(Cl)c(C#CCCCC#N)cc2nc1NCC",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a piperazine ring connected to a fused diazole and chlorinated benzene ring. Additionally, it features a hexa-1,6-diyne nitrile substituent. Functional groups present include secondary amines, aromatic rings with chloro substitution, alkynes, and nitrile groups.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity through hydrogen bonding from the amine groups and \u03c0-\u03c0 stacking interactions from the aromatic rings. The chloro substituent may enhance binding affinity by providing additional hydrophobic interactions.",
            "Limitation in Source Molecule for Property": "The presence of the nitrile and alkyne groups may reduce the molecule's solubility and metabolic stability. Additionally, the chloro substituent could lead to off-target effects and toxicity concerns, potentially limiting its therapeutic applicability.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce polar functional groups to improve solubility and metabolic stability. Replace the nitrile and alkyne moieties with more metabolically stable groups such as amides or ether linkages. Modify the aromatic substitution pattern to optimize binding interactions and reduce potential toxicity by replacing the chloro group with a less reactive substituent.",
            "Final Target Molecule": "CCNc1nc2cc(O)c(C(=O)CCCC)cc2nc1NCC"
        }
    },
    {
        "src_smiles": "c1ccc(Cn2c(-c3ccccc3)nc3ccccc32)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a benzene ring substituted with a fused bicyclic system. The bicyclic moiety includes a pyrimidine ring connected to two phenyl rings, forming a triaza-phenyl structure. This structure provides a planar aromatic system with multiple potential sites for hydrogen bonding and hydrophobic interactions.",
            "Property Analysis": "GSK3-beta inhibitors typically interact with the kinase's ATP-binding site, requiring planar, aromatic structures for stacking interactions, as well as hydrogen bond donors and acceptors to engage with key amino acid residues. Effective inhibitors often have substituents that enhance binding affinity and selectivity through additional interactions.",
            "Limitation in Source Molecule for Property": "The source molecule may lack specific functional groups necessary for optimal hydrogen bonding and may not have sufficient planarity or electronic properties required for strong interactions with GSK3-beta. Additionally, the absence of substituents that can enhance binding affinity and selectivity may limit its inhibitory potency.",
            "Optimization for Source Molecule": "Introduce electron-donating groups to enhance binding affinity and add hydrogen bond donors/acceptors to interact with the kinase's active site. Modify the bicyclic system to increase planarity and rigidity, ensuring better stacking interactions. Incorporate substituents that improve selectivity by occupying additional binding pockets unique to GSK3-beta.",
            "Final Target Molecule": "c1ccc(Cn2c(-c3ccccc3)nc(c3ccccc3)C2=O)cc1"
        }
    },
    {
        "src_smiles": "COc1ccc2nc(NC(=O)CSc3ccccc3)sc2c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a methoxy-substituted phenyl ring connected to a bicyclic thiazole system. This thiazole is further linked via a urea linker to a thiophenyl group. The overall structure comprises aromatic rings and heteroatoms that facilitate potential interactions with biological targets.",
            "Property Analysis": "The molecule acts as an inhibitor of Glycogen Synthase Kinase 3-beta (GSK3-beta) through interactions that likely involve hydrogen bonding and hydrophobic contacts within the kinase's active site. Its structural components provide the necessary framework for binding affinity and specificity.",
            "Limitation in Source Molecule for Property": "The current structure may exhibit limited binding affinity and selectivity towards GSK3-beta due to suboptimal positioning of functional groups, lack of key interactions within the kinase's active site, or insufficient molecular flexibility to adapt to binding conformations.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce electron-withdrawing groups on the phenyl rings to strengthen hydrogen bonding with the kinase. Modify the linker to increase flexibility, allowing better accommodation in the active site. Replace the thiophene moiety with a more hydrophilic heterocycle to improve selectivity and reduce off-target effects.",
            "Final Target Molecule": "COc1ccc2nc(NC(=O)CSc3c(F)ccc(F)c3)sc2c1"
        }
    },
    {
        "src_smiles": "c1ccc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a benzene ring substituted at the para position with a 2,4-diphenylpyrimidine core. The pyrimidine ring is further substituted with two phenyl groups, providing a planar and aromatic structure that is conducive to stacking interactions with biological targets.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against GSK3-beta due to its aromatic system, which can facilitate \u03c0-\u03c0 interactions within the kinase's active site. The presence of nitrogen atoms in the pyrimidine ring may form hydrogen bonds, enhancing binding affinity and specificity.",
            "Limitation in Source Molecule for Property": "The source molecule may lack optimal binding interactions necessary for high potency and selectivity towards GSK3-beta. Additionally, the absence of polar functional groups could result in poor solubility and bioavailability, limiting its effectiveness as a drug candidate.",
            "Optimization for Source Molecule": "Introduce polar substituents such as hydroxyl or amino groups on the phenyl rings to enhance solubility and enable additional hydrogen bonding with GSK3-beta. Modify the pyrimidine core with electron-withdrawing groups to increase binding affinity and selectivity. Ensure steric compatibility to maintain favorable interactions within the kinase active site.",
            "Final Target Molecule": "c1ccc(-c2nc(-c3cc(O)ccc3)c(-c4ccccc4)[nH]2)cc1"
        }
    },
    {
        "src_smiles": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, represented by the SMILES string COc1n[nH]c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncc12, consists of a central pyrimidine ring fused with a piperazine ring. It features a methoxy group attached to the pyrimidine, a urea linkage connecting to a chlorophenyl group, and a fluorophenyl moiety, which might contribute to its binding affinity through hydrophobic interactions and potential hydrogen bonding.",
            "Property Analysis": "GSK3-beta inhibition is influenced by the molecule's ability to interact with the kinase's active site, relying on hydrogen bonding, hydrophobic interactions, and appropriate molecular conformation. The presence of electronegative substituents like fluorine can enhance binding affinity through dipole interactions, while the urea linkage may form hydrogen bonds critical for inhibitory activity.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding affinity due to limited hydrogen bond donors/acceptors in key positions, potential steric hindrance affecting proper fit within the GSK3-beta active site, and insufficient hydrophobic interactions that could stabilize the inhibitor-kinase complex.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications could include introducing additional hydrogen bond donors or acceptors to strengthen interactions with the kinase, substituting or adding hydrophobic groups to increase van der Waals interactions, and adjusting the molecular conformation to better fit the active site. Specifically, adding a methyl group to improve hydrophobic contact or introducing a hydroxyl group to provide additional hydrogen bonding capacity could be beneficial.",
            "Final Target Molecule": "COc1n[nH]c2cc(NC(=O)NC(C)(C)c3ccc(F)cc3)ncc12"
        }
    },
    {
        "src_smiles": "COc1ccc(C(=O)OCC(=O)NCc2ccco2)cc1OC",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a di-methoxyphenyl ring attached to an ester-linked amide, which is further connected to an isoxazole moiety. The presence of electron-donating methoxy groups may influence binding interactions.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity, likely through interactions with the kinase's ATP-binding pocket. The amide and ester functionalities may form key hydrogen bonds essential for inhibition.",
            "Limitation in Source Molecule for Property": "Limited binding affinity and selectivity towards GSK3-beta. The molecule may also suffer from suboptimal pharmacokinetic properties such as solubility and metabolic stability.",
            "Optimization for Source Molecule": "Introduce substituents that enhance binding affinity and selectivity, such as a halogen on the phenyl ring to engage in halogen bonding. Modify the ester linkage to a more stable bioisostere to improve metabolic stability. Enhance solubility by adding polar functional groups.",
            "Final Target Molecule": "COc1ccc(C(=O)NCC(=O)NCc2ccco2)cc1OC(F)F"
        }
    },
    {
        "src_smiles": "O=C1NC(=O)C(=Cc2ccc(O)cc2)N1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a diketopiperazine derivative featuring a cyclic dipeptide core with two carbonyl groups. It includes a vinyl-linked aromatic ring substituted with a hydroxyl group, which may facilitate hydrogen bonding and pi-stacking interactions.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity due to its ability to form hydrogen bonds and engage in hydrophobic interactions within the kinase's active site. The presence of the hydroxyl-substituted aromatic ring may enhance binding affinity.",
            "Limitation in Source Molecule for Property": "The source molecule may have limited potency and selectivity for GSK3-beta. Additionally, the hydroxyl group could lead to poor metabolic stability and lower bioavailability. The rigid cyclic structure might also restrict optimal binding interactions.",
            "Optimization for Source Molecule": "Introduce electron-donating or electron-withdrawing substituents on the aromatic ring to enhance binding affinity and selectivity. Modify the cyclic dipeptide core to increase flexibility and improve interactions with the kinase. Replace or protect the hydroxyl group to enhance metabolic stability and bioavailability.",
            "Final Target Molecule": "O=C1NC(=O)C(=Cc2ccc(OCC)cc2)N1"
        }
    },
    {
        "src_smiles": "CC(CO)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a central pyrimidine core fused to a thiazole ring, substituted with a propanol chain and a methoxy linker. Additionally, it features a side chain containing an amide linkage connecting to a benzyl group. The overall structure combines heterocyclic systems with aliphatic and aromatic substituents, potentially contributing to its biological activity.",
            "Property Analysis": "The molecule exhibits moderate inhibition of Glycogen Synthase Kinase 3-beta (GSK3-beta). The presence of the pyrimidine and thiazole rings may facilitate interactions with the kinase's ATP-binding site, while the benzyl amide moiety could enhance binding affinity through hydrophobic interactions.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding affinity and selectivity towards GSK3-beta due to limited hydrogen bonding interactions and potential steric hindrance from bulky substituents. Additionally, the solubility and bioavailability of the molecule might be adversely affected by the lipophilic benzyl group.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications include introducing electron-withdrawing groups on the benzyl amide to strengthen hydrogen bonding with the kinase, reducing the bulkiness of the substituents to minimize steric clashes, and incorporating polar functional groups to improve solubility and bioavailability. Structural rigidity can also be increased to favor specific binding conformations.",
            "Final Target Molecule": "CC(CO)COc1n[nH]c2cc(NC(=O)N(C)c3ccccc3)cnc12"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a central amino group linked to a benzyl group and an amide bond. The amide is connected to a fused heterocyclic system containing a pyrazole ring substituted with a methoxyphenyl group. The molecule features multiple aromatic rings which may contribute to pi-stacking interactions.",
            "Property Analysis": "The molecule exhibits moderate inhibition of GSK3-beta with reasonable selectivity. The presence of the pyrazole and amide functionalities likely facilitates hydrogen bonding with the kinase active site. However, the overall molecular weight and lipophilicity may affect its drug-like properties.",
            "Limitation in Source Molecule for Property": "The current molecule may suffer from suboptimal binding affinity due to limited hydrogen bonding interactions and potentially high lipophilicity, which could lead to poor solubility and off-target effects. Additionally, the lack of specific substituents may limit interactions with key residues in the GSK3-beta active site.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors or acceptors to enhance binding interactions with GSK3-beta. Modify the aromatic rings to include substituents that can engage in specific interactions with the kinase, such as halogens or fluorine to improve binding affinity and selectivity. Reduce lipophilicity by introducing polar functional groups to improve solubility and pharmacokinetic properties.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccc(F)cc3)c2cn1)c1ccccc1"
        }
    },
    {
        "src_smiles": "CC(c1ccncc1)c1nnc(Nc2ccc(Cl)cc2)c2ccccc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule CC(c1ccncc1)c1nnc(Nc2ccc(Cl)cc2)c2ccccc12 consists of a central diazole ring fused to two aromatic rings. The molecule features a chlorophenyl group attached to one of the aromatic rings and a methyl group linked to a pyridine ring. The presence of multiple aromatic systems and nitrogen-containing heterocycles suggests potential for pi-stacking and hydrogen bonding interactions.",
            "Property Analysis": "The molecule exhibits inhibitory activity against GSK3-beta, a kinase involved in various cellular processes. The aromatic rings and nitrogen atoms likely contribute to binding interactions within the active site of GSK3-beta, enhancing affinity. The chlorophenyl group may play a role in hydrophobic interactions, further stabilizing the inhibitor-enzyme complex.",
            "Limitation in Source Molecule for Property": "While the source molecule is active against GSK3-beta, its potency may be limited by suboptimal binding affinity or selectivity. The presence of multiple aromatic rings may lead to off-target interactions, reducing selectivity. Additionally, metabolic stability and solubility could be concerns that affect the overall efficacy of the inhibitor.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, modifications could include: 1) Introducing electron-donating or withdrawing groups to enhance binding affinity; 2) Modifying the chlorophenyl group to improve selectivity and reduce off-target effects; 3) Adding polar functional groups to increase solubility without compromising binding; 4) Reducing the number of aromatic rings to enhance selectivity and metabolic stability.",
            "Final Target Molecule": "CC(c1ccncc1)c1nnc(Nc2ccc(Cl)cc2)c2c(Cl)cccc12"
        }
    },
    {
        "src_smiles": "CCC(O)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a three-carbon chain with a hydroxyl group (CCC(O)) connected via an ether linkage to a fused bicyclic system containing nitrogen atoms. The bicyclic structure includes a triazole ring fused to a pyridine ring, which is substituted with a urea moiety linked to a benzyl group.",
            "Property Analysis": "The molecule exhibits key features beneficial for GSK3-beta inhibition, including hydrogen bond donors and acceptors that facilitate binding to the kinase's active site. The benzyl group provides hydrophobic interactions essential for strong binding affinity. Additionally, the overall molecular framework supports favorable pharmacokinetic properties such as membrane permeability.",
            "Limitation in Source Molecule for Property": "The presence of the hydroxyl group and ether linkage introduces polarity, which may reduce the molecule's membrane permeability and binding affinity. Furthermore, the urea linkage is susceptible to metabolic degradation, potentially affecting the molecule's stability and bioavailability.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibitory activity, replace the polar hydroxyl group with a methyl group to increase hydrophobicity and membrane permeability. Modify the ether linkage to a more stable linkage and convert the urea moiety to an amide to improve metabolic stability. Additionally, introduce additional hydrophobic substituents to strengthen interactions within the kinase's binding pocket.",
            "Final Target Molecule": "CC(C)COc1n[nH]c2cc(NC(=O)C(C)c3ccccc3)ncc12"
        }
    },
    {
        "src_smiles": "COc1ccccc1-c1ccc(CC(NC(=O)Cn2cnnn2)C(=O)O)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a methoxyphenyl group connected to a benzene ring, which is further substituted with a side chain containing a tertiary amine linked to an amide bond and a triazole ring, along with a carboxylic acid group. The presence of electron-donating (methoxy) and electron-withdrawing (carboxylic acid, amide) groups may influence its binding interactions with GSK3-beta.",
            "Property Analysis": "The molecule possesses functional groups commonly associated with kinase inhibition, including the triazole and amide functionalities, which may facilitate interactions with the ATP-binding site of GSK3-beta. These groups can participate in hydrogen bonding and \u03c0-\u03c0 stacking, potentially enhancing inhibitory activity.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal spatial orientation and electronic complementarity for strong binding to key residues in the GSK3-beta active site, potentially resulting in limited binding affinity and selectivity. Additionally, the presence of the carboxylic acid group could negatively impact cell permeability and pharmacokinetic properties.",
            "Optimization for Source Molecule": "Modify the carboxylic acid to a bioisostere such as an ester to improve cell permeability while retaining key interactions. Introduce substituents on the aromatic rings to enhance \u03c0-\u03c0 stacking and hydrogen bonding interactions with the kinase. Optimize the linker length and flexibility between the aromatic core and the triazole to improve binding affinity and selectivity for GSK3-beta.",
            "Final Target Molecule": "COc1ccccc1-c1ccc(CC(NC(=O)Cn2cnnn2)C(=O)OC)cc1"
        }
    },
    {
        "src_smiles": "Brc1cnc(N2CCOCC2)nc1Nc1cc(C2CC2)[nH]n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule Brc1cnc(N2CCOCC2)nc1Nc1cc(C2CC2)[nH]n1 consists of a brominated triazole core connected to a piperazine-ethylene oxide moiety and a phenylnicotinamide fragment. The molecule features multiple nitrogen heterocycles which may contribute to hydrogen bonding and pi-stacking interactions.",
            "Property Analysis": "GSK3-beta inhibition activity is influenced by the ability of the molecule to interact with key amino acid residues in the enzyme's active site. Effective inhibitors often form hydrogen bonds and hydrophobic interactions, while maintaining optimal molecular flexibility and conformational stability.",
            "Limitation in Source Molecule for Property": "The source molecule may exhibit suboptimal binding affinity due to limited hydrophobic interactions and potential steric hindrance from the bulky bromine substituent. Additionally, the presence of multiple nitrogen atoms might lead to excessive hydrogen bonding, reducing selectivity.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, reduce steric bulk by modifying the bromine substituent to a smaller halogen or removing it entirely. Introduce additional hydrophobic groups to improve binding within the enzyme's hydrophobic pocket. Optimize the piperazine-ethylene oxide linker to increase flexibility and enhance hydrogen bonding with key residues.",
            "Final Target Molecule": "c1cnc(nc1Nc1cc(CCCOCC)cc1)[nH]n1"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1 consists of a central piperazine ring fused with a pyrimidine moiety. It features an amide linkage connecting to a substituted aniline group. The molecule contains multiple aromatic rings, including benzene and heterocyclic structures, which may contribute to its binding affinity through \u03c0-\u03c0 interactions.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta) due to its ability to interact with the kinase's active site. The presence of multiple hydrogen bond donors and acceptors, along with aromatic systems, suggests favorable interactions with key residues in GSK3-beta.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding affinity and selectivity towards GSK3-beta. Additionally, the molecule might have poor cell permeability or metabolic stability due to the presence of multiple aromatic rings and amide bonds, potentially limiting its efficacy as a therapeutic agent.",
            "Optimization for Source Molecule": "Introduce substituents that enhance hydrogen bonding and hydrophobic interactions within the GSK3-beta active site. Consider adding a methyl group to improve metabolic stability or fluorine atoms to enhance binding affinity and selectivity. Modify the amide linkage to a more rigid or bioisosteric group to increase binding specificity and reduce metabolic susceptibility.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1C)c1ccccc1F"
        }
    },
    {
        "src_smiles": "CC(CCn1ccc(-c2ccc(F)cc2)cc1=O)(C(=O)NO)S(C)(=O)=O",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, CC(CCn1ccc(-c2ccc(F)cc2)cc1=O)(C(=O)NO)S(C)(=O)=O, consists of a central carbon bonded to a secondary amine connected to a substituted aromatic ring containing a fluorine atom. It also features a nitroso group (C=O-N), a sulfonyl group (S(C)(=O)=O), and a ketone functional group on the aromatic ring. The molecule has both hydrophobic regions from the aromatic rings and polar functional groups that can participate in hydrogen bonding.",
            "Property Analysis": "The molecule exhibits inhibition of GSK3-beta, a kinase involved in various cellular processes. The presence of the fluorinated aromatic ring may enhance binding affinity through hydrophobic and electronic interactions. The nitroso and sulfonyl groups can form hydrogen bonds and potentially interact with key amino acid residues in the active site of GSK3-beta, contributing to its inhibitory activity.",
            "Limitation in Source Molecule for Property": "The source molecule may have limited selectivity towards GSK3-beta due to the presence of multiple reactive functional groups, which could interact with other kinases or proteins, leading to off-target effects. Additionally, the steric bulk from the aromatic rings and sulfonyl groups might hinder optimal binding orientation within the GSK3-beta active site, reducing inhibitory efficiency.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the molecule can be optimized by reducing steric hindrance around the binding site to allow better fit and orientation. Introducing substituents that increase hydrogen bonding specificity with GSK3-beta could improve binding affinity. Modifying or replacing the nitroso group with a more stable hydrogen bond acceptor may enhance selectivity and reduce potential off-target interactions. Additionally, optimizing the fluorinated aromatic ring substitution pattern could further refine hydrophobic interactions within the kinase's active site.",
            "Final Target Molecule": "CC(CCn1ccc(-c2ccc(F)cc2)cc1=O)(C(=O)N)S(C)(=O)=O"
        }
    },
    {
        "src_smiles": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule contains a thioether linkage (\u2013S\u2013) connected to a dihydropyrimidine core with two nitrogen atoms. It features a methoxyethyl side chain (COCC) and a benzamide substituent attached via a urea linker. The fused ring system includes a pyrimidine ring connected to a pyridine ring, enhancing molecular rigidity and potential binding interactions.",
            "Property Analysis": "The molecule exhibits moderate inhibition of GSK3-beta, likely due to its ability to interact with the ATP-binding pocket of the kinase. The presence of hydrogen bond donors and acceptors facilitates interactions with key amino acid residues, contributing to its inhibitory activity.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited specificity and suboptimal binding affinity. The thioether linkage and the urea linker might not form sufficient hydrogen bonds or hydrophobic interactions required for stronger inhibition. Additionally, the flexibility of the side chains could reduce binding efficiency.",
            "Optimization for Source Molecule": "Introduce substituents that enhance hydrogen bonding and hydrophobic interactions within the GSK3-beta active site. Replace the thioether linkage with a more rigid amide bond to increase binding affinity. Modify the benzamide moiety to include halogen atoms, such as fluorine or chlorine, to improve lipophilicity and specificity. Optimize the side chains to better fit the ATP-binding pocket, potentially adding methyl or methoxy groups to enhance interactions.",
            "Final Target Molecule": "COCNCc1nnc(C)c2cc(NC(=O)C(F)c3ccccc3)ccs12"
        }
    },
    {
        "src_smiles": "COCCOc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a bicyclic core featuring a fused pyridine and benzene ring system. It includes an ether linkage (COCCO) attached to the nitrogen of the pyridine ring. Additionally, there is an amide functional group connecting to a benzyl moiety through a secondary amine linkage, which introduces a phenyl substitution.",
            "Property Analysis": "GSK3-beta inhibitors typically interact with the kinase's ATP-binding site or allosteric sites, requiring specific hydrogen bond donors/acceptors and hydrophobic regions for optimal binding. The current molecule presents both polar and hydrophobic regions that may facilitate interaction with GSK3-beta, potentially inhibiting its kinase activity.",
            "Limitation in Source Molecule for Property": "The existing structure may suffer from limited selectivity towards GSK3-beta due to potential off-target interactions facilitated by the benzyl moiety. Additionally, the molecule might exhibit suboptimal bioavailability and metabolic stability, reducing its efficacy as a therapeutic agent.",
            "Optimization for Source Molecule": "Introduce substituents that enhance selectivity by increasing interactions within the unique pockets of GSK3-beta. Modifying the benzyl group to incorporate heteroatoms could improve binding specificity. Additionally, optimizing the ether linkage to reduce metabolic liabilities and enhance pharmacokinetic properties would be beneficial.",
            "Final Target Molecule": "COCCOc1n[nH]c2cc(NC(=O)NC(C)c3c[nH]cc3)ncc12"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule comprises a central ethylamine linked to a benzamide moiety and a fused heterocyclic system. The structure includes a piperazine ring connected to a benzene ring and a pyrazole-fused pyridine ring system. Additionally, there is a fluorinated side chain (CNCC(F)F) attached to the pyrazole ring, which may influence binding interactions and metabolic stability.",
            "Property Analysis": "The molecule acts as an inhibitor of Glycogen Synthase Kinase 3-beta (GSK3-beta), a serine/threonine kinase involved in various cellular processes including glycogen metabolism and signaling pathways. The presence of the fluorinated side chain is likely to enhance binding affinity and selectivity towards GSK3-beta by engaging in specific interactions within the kinase's active site. The overall structure facilitates hydrogen bonding and hydrophobic interactions essential for effective inhibition.",
            "Limitation in Source Molecule for Property": "The current structure may exhibit suboptimal selectivity, potentially interacting with other kinases due to the conserved nature of ATP-binding sites. Additionally, the molecular size and polarity could limit cell permeability and bioavailability. The absence of key functional groups that enhance specific interactions with GSK3-beta may also reduce inhibitory potency.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, structural modifications should focus on increasing selectivity and binding affinity. Introducing substituents that can form additional hydrogen bonds or hydrophobic interactions within the GSK3-beta active site is desirable. For instance, adding a methyl group to the benzene ring could improve hydrophobic interactions, while introducing a methoxy group might facilitate hydrogen bonding. Modifying the fluorinated side chain to a more rigid structure could enhance binding specificity. Additionally, reducing molecular polarity may improve cell permeability and overall bioavailability.",
            "Final Target Molecule": "CC(C)NC(=O)Nc1cc(CO)c2[nH]nc(CNCC(F)F)c2cn1)c1ccccc1"
        }
    },
    {
        "src_smiles": "CCCNC(=O)N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule contains a propyl amide linkage (CCCNC(=O)N) connected to a substituted piperidine ring (N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO). The piperidine ring is further substituted with a nitrile group (C#N), a biphenyl-like aromatic system (c2ccc(C3=CCCCC3)cc2), and a hydroxymethyl group (C1CO). The presence of cyclohexyl and aromatic rings imparts both hydrophobic and potential hydrogen bonding characteristics to the molecule.",
            "Property Analysis": "The molecule exhibits structural features favorable for GSK3-beta inhibition, including the amide linkage which can form hydrogen bonds with the kinase active site, and the aromatic rings which facilitate hydrophobic interactions. The nitrile group may act as a hydrogen bond acceptor, enhancing binding affinity. The hydroxymethyl group introduces additional polarity, potentially improving solubility and interaction with the enzyme.",
            "Limitation in Source Molecule for Property": "Despite its favorable features, the source molecule may suffer from suboptimal binding affinity and selectivity towards GSK3-beta. The single nitrile group might not provide sufficient hydrogen bonding interactions, and the cyclohexyl moiety could limit the molecule\u2019s ability to interact dynamically within the active site. Additionally, the overall molecular size and flexibility may hinder optimal fit and specificity.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibitory activity, introduce additional hydrogen bond donors or acceptors to strengthen interactions with the kinase. Replace the cyclohexyl group with a more rigid or planar aromatic system to improve binding specificity. Modify the nitrile group to a more versatile functional group such as an amide or hydroxyl to increase hydrogen bonding capacity. Incorporate substituents on the biphenyl system to engage in pi-stacking or other specific interactions within the active site. Optimize the hydroxymethyl group to balance hydrophilicity and binding interactions.",
            "Final Target Molecule": "CCCNC(=O)N1C(C=O)C(c2ccc(C3=CC=CC=C3)cc2)C1CO"
        }
    },
    {
        "src_smiles": "Cc1cc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)cc(C)n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a substituted benzene ring with two methyl groups, a fluorophenyl moiety, and a triazole-linked piperazine-ethylene oxide proximal structure. The core structure includes a trifluoromethyl-substituted phenyl group attached to a triazole ring, which is further connected to a piperazine ring bridged by an ethylene oxide linker.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity due to the presence of the triazole and piperazine moieties, which are known pharmacophores in kinase inhibitors. The fluorine substituent may enhance binding affinity and metabolic stability.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding affinity and selectivity towards GSK3-beta. The ethylene oxide linker could introduce flexibility that reduces binding specificity, and the benzene ring substitution pattern may not fully engage the active site interactions required for potent inhibition.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, introduce rigidifying elements to reduce linker flexibility, enhance hydrogen bonding capabilities, and optimize electronic properties for better active site interactions. Adding polar functional groups could increase binding affinity, while modifying the substitution pattern on the benzene ring may improve selectivity.",
            "Final Target Molecule": "Cc1c(C)cc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)cc1C(F)(F)C"
        }
    },
    {
        "src_smiles": "COc1c(N2CCCC(N)C2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a bicyclic structure comprising a substituted pyridine ring fused with a piperazine ring. Key functional groups include a methoxy group, two amino groups attached to the pyridine ring, a fluorine substituent, a carboxamide linkage, and a cyclopropylmethyl substituent. Additionally, the molecule contains a carboxylic acid moiety, enhancing its polarity.",
            "Property Analysis": "The molecule exhibits moderate inhibition of Glycogen Synthase Kinase 3-beta (GSK3-beta) due to its ability to interact with the ATP-binding site of the enzyme. The presence of amino groups allows for hydrogen bonding with key residues, while the fluorine atom may contribute to binding affinity through halogen bonding or hydrophobic interactions.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal selectivity towards GSK3-beta, potentially interacting with other kinases due to the planar aromatic system. Additionally, the polar carboxylic acid group may reduce cell permeability, limiting the molecule's bioavailability and overall inhibitory effectiveness.",
            "Optimization for Source Molecule": "Introduce a substituent that enhances selectivity by adding a bulky group to occupy a unique hydrophobic pocket in GSK3-beta, thereby reducing off-target kinase interactions. Modify or esterify the carboxylic acid group to improve cell permeability while maintaining the ability to form essential hydrogen bonds within the active site. Incorporate a methyl or ethyl group on the piperazine ring to increase lipophilicity and binding affinity.",
            "Final Target Molecule": "COc1c(N2CCN(CC)C2)c(F)c(N)c2c(=O)c(C(=O)OCC)cn(C3CC3)C4CC4)c12"
        }
    },
    {
        "src_smiles": "CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C(C)CN1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a piperazine core substituted with a complex aromatic system containing multiple fluorine atoms, a cyclobutane ring, and several carbonyl groups. The presence of nitrogen atoms within the ring and the aromatic system suggests potential sites for hydrogen bonding and electronic interactions.",
            "Property Analysis": "The molecule exhibits potential as a GSK3-beta inhibitor due to the presence of fluorinated aromatic rings and carbonyl functionalities, which may interact with the kinase's active site. The piperazine moiety can enhance solubility and provide rigidity to the molecular framework, potentially improving binding affinity.",
            "Limitation in Source Molecule for Property": "The bulky cyclobutane ring may introduce steric hindrance, limiting optimal binding to GSK3-beta. Additionally, the high degree of fluorination could lead to decreased solubility and increased metabolic stability, potentially affecting bioavailability.",
            "Optimization for Source Molecule": "Modify the cyclobutane ring to a less sterically demanding moiety, such as a cyclopropyl or methyl substituent, to reduce hindrance in the binding site. Introduce polar functional groups to enhance solubility without compromising binding affinity. Reduce the number of fluorine atoms to balance lipophilicity and metabolic stability.",
            "Final Target Molecule": "CC1CN(C2CC(C(F)C3=NC(=O)C(C(=O)O)CN(C4CC4)C3c2F)N)CN1)C"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3cncs3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features an ethyl group attached to a urea linkage, which connects to a fused heterocyclic system containing a thiazole ring. Additionally, a phenyl ring is present, providing potential sites for further functionalization.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against GSK3-beta, likely due to the presence of the heterocyclic core which can interact with the kinase's active site. The phenyl ring may contribute to hydrophobic interactions, enhancing binding affinity.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal binding interactions required for strong and selective inhibition of GSK3-beta. Additionally, the molecule might have suboptimal pharmacokinetic properties, such as solubility and metabolic stability, which could limit its efficacy as a drug candidate.",
            "Optimization for Source Molecule": "Introduce electron-withdrawing groups on the phenyl ring to enhance binding affinity through increased hydrogen bonding and pi-stacking interactions. Modify the thiazole ring to improve selectivity by adding substituents that better fit the GSK3-beta active site. Additionally, optimize the urea linkage to improve metabolic stability and pharmacokinetic properties.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2ncc(OCc3cscn3)c2cn1)c1c(F)ccc(C(F)(F)F)cc1"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(S(C)(=O)=O)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule contains a central carbon connected to a methyl group, a urea linkage, and a phenyl ring. The urea moiety is linked to a fused bicyclic system comprising a pyrimidine ring fused with a thieno ring, which is further substituted with a sulfonamide group. This structure provides multiple hydrogen bond donors and acceptors, as well as aromatic systems that can facilitate pi-stacking interactions.",
            "Property Analysis": "The molecule exhibits moderate molecular weight, reasonable lipophilicity, and multiple hydrogen bonding sites, which are favorable for enzyme binding. The presence of both hydrophobic aromatic rings and polar functional groups may contribute to balanced solubility and membrane permeability. However, the sulfonamide group may introduce potential metabolic liabilities and off-target interactions.",
            "Limitation in Source Molecule for Property": "The sulfonamide group in the thieno-pyrimidine system may reduce selectivity and increase the risk of metabolic instability. Additionally, the urea linkage could be susceptible to hydrolysis, potentially decreasing the molecule's stability and bioavailability. The overall rigidity of the fused ring system might limit conformational flexibility necessary for optimal binding to GSK3-beta.",
            "Optimization for Source Molecule": "Introduce a methyl or fluorine substituent on the phenyl ring to enhance lipophilicity and binding affinity. Replace the urea linkage with a more metabolically stable amide or carbamate group to improve stability. Modify the sulfonamide group to a sulfonyl fluoride to increase selectivity towards GSK3-beta. Incorporate a bioisostere for the fused ring system to enhance conformational flexibility and optimize interactions within the GSK3-beta active site.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(S(F)C)c2cn1)c1ccccc1"
        }
    },
    {
        "src_smiles": "CC(C)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, CC(C)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1, features a central pyrimidine ring substituted with two chlorine atoms on adjacent phenyl rings. The molecule includes an N-methylacetamide side chain and an isopropylamine group, indicating potential hydrogen bonding capabilities and hydrophobic interactions.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against GSK3-beta due to its planar aromatic structure, which may facilitate \u03c0-\u03c0 stacking interactions with the kinase's active site. The presence of electron-withdrawing chlorine substituents could enhance binding affinity by stabilizing the molecule-Kinase complex through halogen bonding.",
            "Limitation in Source Molecule for Property": "The current molecular structure may suffer from limited solubility and suboptimal binding specificity. The bulky chlorine atoms could hinder optimal binding orientation, and the isopropylamine group may introduce steric hindrance, reducing the molecule's overall efficacy as a GSK3-beta inhibitor.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce a fluorine atom in place of one chlorine to reduce steric hindrance and potentially increase binding affinity through strong C-F interactions. Modify the isopropylamine group to a smaller alkyl chain to improve binding orientation and reduce steric clash. Additionally, add a hydroxyl group to increase solubility and enable hydrogen bonding with amino acid residues in the kinase active site.",
            "Final Target Molecule": "CC(C)Nc1ncc2cc(-c3c(F)cccc3Cl)c(=O)n(C)c2n1O"
        }
    },
    {
        "src_smiles": "Cn1c(-c2ccnc(Oc3ccccc3)n2)c(-c2ccc(F)cc2)c(=O)n1C",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a triazole core bonded to two aromatic rings. One aromatic ring is substituted with a fluorine atom, and the other is connected to a nitropyridine moiety which is further linked to a methoxyphenyl group. An amide linkage is present within the triazole core, contributing to the overall structure and potential binding interactions.",
            "Property Analysis": "The molecule exhibits inhibitory activity against GSK3-beta, likely through hydrogen bonding and hydrophobic interactions within the enzyme's active site. The presence of electron-withdrawing groups such as fluorine may enhance binding affinity by stabilizing interactions. Additionally, the nitropyridine moiety may contribute to specificity and potency of inhibition.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited selectivity due to the presence of multiple aromatic systems, which can lead to off-target interactions. The methoxy group could introduce steric hindrance, potentially reducing binding efficiency. Furthermore, the nitro group may affect the molecule's metabolic stability and pharmacokinetic properties adversely.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, the methoxy group can be replaced with a smaller substituent to reduce steric hindrance and enhance binding efficiency. Introducing electron-donating groups in strategic positions could enhance hydrogen bonding with the active site residues. Additionally, modifying the nitropyridine moiety to a more metabolically stable group can improve selectivity and pharmacokinetic properties. Incorporating a methyl group adjacent to the fluorine atom may increase lipophilicity and binding affinity.",
            "Final Target Molecule": "Cn1c(-c2ccnc(Oc3ccccc3)n2)c(-c2ccc(F)Ccc2)c(=O)n1C"
        }
    },
    {
        "src_smiles": "COc1cc(OC)cc(-c2nnc(SCC(=O)c3ccccc3)o2)c1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a 1,2-dimethoxybenzene core substituted with a heterocyclic moiety. Specifically, it contains two methoxy groups attached to a benzene ring, and a triazole-like ring connected via a thioether linkage. Additionally, there is an acetylated phenyl group attached to the sulfur atom, introducing an ester functional group to the molecule.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against GSK3-beta due to the presence of the heterocyclic triazole ring, which can engage in hydrogen bonding and pi-stacking interactions within the active site of the enzyme. The methoxy groups may contribute to the molecule's overall lipophilicity, enhancing cell membrane permeability and bioavailability.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited selectivity towards GSK3-beta due to the absence of specific functional groups that can interact uniquely with the enzyme's active site. Additionally, the ester linkage might be susceptible to hydrolysis, potentially reducing metabolic stability and in vivo efficacy.",
            "Optimization for Source Molecule": "Introduce a substituent that can form additional hydrogen bonds with key residues in the GSK3-beta active site to enhance binding affinity and selectivity. Replace the ester linkage with a more metabolically stable amide bond to improve the molecule's stability. Additionally, modifying the methoxy groups to fluorine atoms could increase binding interactions and reduce metabolic susceptibility.",
            "Final Target Molecule": "COc1cc(F)c(O)c(-c2nnc(SC(C=O)Nc3ccccc3)o2)c1"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCCO3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of an ethylamine group linked via an amide bond to a heterocyclic core. It features a phenyl ring attached to the nitrogen atom and a trioxane ring connected through an ether linkage to the heterocycle. The heterocyclic core includes a fused bicyclic system with nitrogen and oxygen heteroatoms, contributing to the molecule's potential for hydrogen bonding and binding interactions.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta). The presence of aromatic and heteroaromatic rings suggests potential strong binding interactions within the ATP-binding pocket of GSK3-beta. The trioxane ring may enhance solubility and provide additional sites for hydrogen bonding, potentially improving pharmacokinetic properties.",
            "Limitation in Source Molecule for Property": "Potential limitations include possible metabolic instability of the trioxane ring, which may be susceptible to enzymatic degradation. Additionally, the molecule's size and conformational rigidity could hinder optimal binding affinity and selectivity for GSK3-beta. There may also be off-target interactions due to the presence of multiple aromatic systems.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibitory activity, modifications can be made to improve binding affinity and metabolic stability. Replacing the trioxane ring with a more stable ether or amine moiety could reduce metabolic vulnerabilities. Introducing additional functional groups that can form hydrogen bonds or hydrophobic interactions within the GSK3-beta active site may enhance specificity and potency. Additionally, reducing the number of aromatic rings or altering their substitution patterns could improve selectivity by minimizing off-target interactions.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCN3)c2cn1)c1ccccc1"
        }
    },
    {
        "src_smiles": "COCc1nc(NC(=O)NC(C)c2ccccc2)cc2[nH]nc(OC)c12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a heterocyclic compound featuring a fused ring system with multiple nitrogen atoms. It contains methoxy groups (COC) attached to the aromatic rings, an amide linkage (NC(=O)N), a substituted benzyl group (NC(C)c2ccccc2), and a triazole-like moiety with an additional methoxy substitution. The molecule exhibits conjugated pi systems which may contribute to its binding interactions.",
            "Property Analysis": "The source molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta), a key enzyme involved in various cellular processes and implicated in diseases such as Alzheimer's and cancer. The presence of multiple hydrogen bond donors and acceptors facilitates interactions with the active site of GSK3-beta, contributing to its inhibitory potency.",
            "Limitation in Source Molecule for Property": "Despite its activity, the source molecule may suffer from suboptimal selectivity, potentially interacting with other kinases leading to off-target effects. Additionally, the molecule's solubility and bioavailability might be limited due to the presence of bulky aromatic groups and multiple methoxy substituents, which can hinder effective cellular uptake and distribution.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, structural modifications can be made to improve selectivity and pharmacokinetic properties. Introducing electron-withdrawing groups on the aromatic rings could increase binding affinity. Reducing steric hindrance by modifying bulky substituents may enhance solubility and bioavailability. Additionally, incorporating bioisosteres for the methoxy groups might improve metabolic stability and reduce off-target interactions.",
            "Final Target Molecule": "COCc1nc(NC(=O)NC(C)c2cc(CF3)ccc2)cc2[nH]nc(Cl)c12"
        }
    },
    {
        "src_smiles": "CC(=O)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features an acetamide linker (CC(=O)N) connecting a pyrimidinone core (c1ncc2cc...c2n1) with two chlorinated phenyl rings. The presence of chlorine atoms on the phenyl rings enhances lipophilicity and may contribute to binding interactions. Additionally, the N-methyl groups on the pyrimidinone core could influence the molecule's conformation and binding affinity.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity due to its pyrimidinone scaffold, which is known to interact with the ATP-binding site of kinases. The chlorinated phenyl rings may facilitate hydrophobic interactions and contribute to the specificity and potency of inhibition. The acetamide linker provides flexibility and could participate in hydrogen bonding with amino acid residues in the kinase active site.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding affinity and selectivity towards GSK3-beta. The absence of additional hydrogen bond donors or acceptors could limit interactions with key residues in the kinase active site. Moreover, the rigid structure might restrict necessary conformational flexibility required for optimal binding.",
            "Optimization for Source Molecule": "Introduce additional polar functional groups, such as hydroxyl or amine groups, to enhance hydrogen bonding capabilities with GSK3-beta active site residues. Modify the acetamide linker to incorporate a methylene spacer, increasing conformational flexibility. Replace one of the chloro substituents with a fluorine atom to potentially improve metabolic stability and binding interactions. Optimize the pyrimidinone core by introducing a 4-substituent that can form additional interactions within the kinase pocket.",
            "Final Target Molecule": "CC(=O)Nc1ncc2cc(-c3c(Cl)cccc3F)c(=O)n(C)c2n1"
        }
    },
    {
        "src_smiles": "O=C(Nc1ccc(Cl)cc1)Nc1ccc(C(F)(F)F)cc1Cl",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a bis(aryl)urea compound featuring two aromatic rings. One aryl group is a 2-chloro-4-trifluoromethylphenyl moiety, while the other is a 2-chloroaniline linked via a urea linker. The molecule contains electron-withdrawing substituents, including chloro and trifluoromethyl groups, which can influence its binding interactions and metabolic stability.",
            "Property Analysis": "The compound exhibits features conducive to kinase inhibition, such as hydrogen bond acceptors and planar aromatic systems that can facilitate interactions with the ATP-binding pocket of GSK3-beta. The trifluoromethyl group may enhance lipophilicity and metabolic stability, potentially improving bioavailability.",
            "Limitation in Source Molecule for Property": "The presence of two chloro substituents may lead to suboptimal binding affinity and selectivity for GSK3-beta. Additionally, the urea linker might introduce metabolic liabilities and reduce the molecule's overall flexibility, potentially hindering optimal interactions within the kinase active site.",
            "Optimization for Source Molecule": "Introduce a morpholine ring adjacent to the urea linker to enhance solubility and provide additional hydrogen bonding opportunities. Replace one of the chloro substituents with a methyl group to reduce potential steric hindrance and improve selectivity. Modify the trifluoromethyl group to a difluoromethyl group to maintain lipophilicity while potentially reducing metabolic resistance.",
            "Final Target Molecule": "O=C(Nc1ccc(Cl)cc1)Nc1ccc(C(F)F)cc1N2CCOCC2"
        }
    },
    {
        "src_smiles": "CCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)CC1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a piperazine ring substituted with a complex fused aromatic system containing fluorine, methoxy, carboxylic acid, and piperidine moieties. The presence of multiple heteroatoms and aromatic rings provides potential sites for hydrogen bonding and hydrophobic interactions, which are crucial for kinase inhibition.",
            "Property Analysis": "The molecule exhibits characteristics favorable for GSK3-beta inhibition, such as multiple hydrogen bond donors and acceptors, as well as hydrophobic regions that can interact with the kinase's active site. However, the existing structure may have limitations in terms of selectivity and metabolic stability.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from limited selectivity towards GSK3-beta over other kinases due to its broad binding capabilities. Additionally, the presence of ester groups could lead to metabolic instability, reducing the molecule's overall efficacy and bioavailability.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications should focus on increasing selectivity and metabolic stability. Replacing ester groups with more stable amide linkages can improve metabolic resistance. Introducing additional hydrophobic or hydrogen-bonding substituents can enhance binding affinity and selectivity towards GSK3-beta. Incorporating fluorine atoms in strategic positions may also improve the molecule's pharmacokinetic properties.",
            "Final Target Molecule": "CCN1CCN(c2c(F)cc3c(N)cc(C4CC4)c3c2OC)CC1"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1 consists of a central quinoline core connected to an aniline derivative. The presence of a trifluoromethyl group enhances the molecule's lipophilicity and metabolic stability. Additionally, the amide linkage provides potential hydrogen bonding interactions essential for binding to the GSK3-beta active site.",
            "Property Analysis": "The source molecule exhibits moderate inhibition of GSK3-beta with an IC50 in the low micromolar range. Its trifluoromethyl group contributes to binding affinity, while the overall structure allows for reasonable cell permeability and metabolic stability.",
            "Limitation in Source Molecule for Property": "Despite its moderate activity, the source molecule lacks optimal selectivity against GSK3-beta, potentially leading to off-target effects. Additionally, the electron-donating nature of the aniline may reduce binding strength in certain active site regions, and the molecule's lipophilicity could be further optimized to enhance pharmacokinetic properties.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, introduce a hydrogen bond donor to enhance interactions within the active site. Modify the trifluoromethyl group to a more electron-withdrawing substituent to increase binding affinity. Additionally, reduce lipophilicity slightly to enhance selectivity and improve solubility. These changes aim to increase potency and selectivity while maintaining favorable pharmacokinetic properties.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(CO)F)c2cn1)c1ccccc1"
        }
    },
    {
        "src_smiles": "COC(C)(C)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a methoxypropyl ether linked to a bicyclic core containing a pyridine and a pyrimidine ring with an amide-benzyl substituent.",
            "Property Analysis": "The molecule exhibits moderate GSK3-beta inhibition with reasonable binding affinity, but may lack optimal selectivity and potency.",
            "Limitation in Source Molecule for Property": "Limited binding interactions within the active site of GSK3-beta, resulting in suboptimal inhibitory potency and selectivity.",
            "Optimization for Source Molecule": "Introduce electron-donating groups to enhance binding affinity and modify substituents to improve selectivity towards GSK3-beta by enhancing hydrogen bonding and hydrophobic interactions.",
            "Final Target Molecule": "CCOC(C)(C)COc1n[nH]c2cc(NC(=O)NC(C)c3ccc(CC)cc3)ncc12"
        }
    },
    {
        "src_smiles": "O=C(Nc1ncc(CCNc2ncnc3ccsc23)s1)NC1CCCCC1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule contains a urea core linked to a 1,2,4-triazole fused with a thiophene ring, and a piperidine moiety. The molecule features hydrogen bond donors and acceptors, as well as aromatic regions that may facilitate \u03c0-\u03c0 interactions.",
            "Property Analysis": "The molecule exhibits potential for GSK3-beta inhibition through hydrogen bonding and hydrophobic interactions. The presence of aromatic rings may enhance binding affinity by interacting with the kinase's active site. Solubility and cell permeability are also important properties to consider.",
            "Limitation in Source Molecule for Property": "The current structure may have limited selectivity towards GSK3-beta due to the lack of specific substituents that enhance binding specificity. Additionally, the molecule might suffer from suboptimal solubility and metabolic stability, potentially affecting its potency and bioavailability.",
            "Optimization for Source Molecule": "Introduce electron-withdrawing groups on the triazole ring to enhance hydrogen bonding with key residues in GSK3-beta. Modify the piperidine ring to a morpholine moiety to improve solubility and metabolic stability. Add a methyl group to the thiophene ring to increase hydrophobic interactions within the kinase's active site.",
            "Final Target Molecule": "O=C(Nc1ncc(CCNCOc2ccsc2C)C(=O)N1CCOCC1)N(C1CCCCC1)C"
        }
    },
    {
        "src_smiles": "O=C(Nc1cc(-c2ccccc2)ccc1O)c1ccc(CN2CCOCC2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features an amide linkage connecting a phenolic aromatic ring substituted with a biphenyl group and another phenyl ring substituted with a piperazine-ethoxy moiety. The presence of multiple aromatic rings may facilitate \u03c0-\u03c0 stacking interactions, while the piperazine-ethoxy group could contribute to binding through hydrogen bonding and hydrophobic interactions.",
            "Property Analysis": "The molecule exhibits potential inhibitory activity against GSK3-beta, likely mediated by the aromatic systems and hydrogen bond donors present. The amide bond may form hydrogen bonds with the kinase, stabilizing the inhibitor within the active site. However, the current binding affinity and selectivity for GSK3-beta over other kinases are not optimized.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from suboptimal binding affinity due to limited interactions within the GSK3-beta active site. Additionally, the flexibility of the piperazine-ethoxy moiety might reduce binding specificity, leading to off-target effects. Metabolic instability and poor pharmacokinetic properties could also hinder its effectiveness as a potent inhibitor.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce substituents that increase hydrogen bonding capacity and optimize \u03c0-\u03c0 interactions within the kinase's active site. Modifying the piperazine-ethoxy moiety to a more rigid structure could improve binding specificity. Adding electron-withdrawing or electron-donating groups on the aromatic rings might enhance binding affinity. Additionally, reducing metabolic liabilities by introducing fluorine atoms could improve metabolic stability.",
            "Final Target Molecule": "O=C(Nc1cc(-c2ccccc2)ccc1O)c1ccc(CN2CCOCC2F)cc1Cl"
        }
    },
    {
        "src_smiles": "COc1ccc(C(O)(Cn2ccnc2)c2ccc(Br)cc2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a methoxy-substituted benzene ring connected to a central carbon atom bearing a hydroxyl group and a secondary amine linked to a pyrimidine ring. Additionally, there is a brominated phenyl ring attached to the central carbon.",
            "Property Analysis": "The compound exhibits potential kinase inhibitory activity due to the presence of aromatic rings capable of \u03c0-\u03c0 interactions, the bromine atom which may enhance binding affinity through halogen bonding, and the hydroxyl group that can form hydrogen bonds with the active site of GSK3-beta.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal interactions within the ATP-binding pocket of GSK3-beta, potentially leading to moderate affinity and selectivity. The methoxy group may limit hydrogen bonding opportunities, and the overall molecular conformation might not favor optimal binding.",
            "Optimization for Source Molecule": "Introduce electron-withdrawing substituents to enhance binding affinity, replace the methoxy group with a hydrogen bond donor or acceptor to improve interactions, modify the linker to enforce a bioactive conformation, and explore different halogen substitutions to increase selectivity and potency.",
            "Final Target Molecule": "COc1ccc(C(NC2=NC=CN2)C3=CC(Br)=CC=C3)C(=O)O)cc1"
        }
    },
    {
        "src_smiles": "CC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)CCN1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, CC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)CCN1, is a tricyclic compound featuring a pyrimidine core fused to a benzamide moiety. It contains both fluorine and chlorine substituents on the aromatic rings, as well as secondary amine groups linked to cyclobutyl rings. The presence of halogen atoms may contribute to the molecule's binding interactions through halogen bonding.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta), a key enzyme involved in various cellular processes and signaling pathways. The current structure allows for potential hydrogen bonding and hydrophobic interactions within the GSK3-beta active site, contributing to its inhibitory effect.",
            "Limitation in Source Molecule for Property": "The presence of bulky cyclobutyl rings may limit the molecule's ability to fit optimally within the GSK3-beta binding pocket, potentially reducing binding affinity. Additionally, the halogen substituents, while useful for binding, might contribute to off-target effects and affect the molecule's overall pharmacokinetic properties.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the cyclobutyl rings can be replaced with more flexible alkyl chains to allow better accommodation within the binding site. Introducing a hydrogen bond donor or acceptor in place of one of the halogens could improve specificity and binding affinity. Additionally, reducing the overall molecular bulk may enhance pharmacokinetic properties and selectivity.",
            "Final Target Molecule": "CC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC)CC3c2OH)CCN1"
        }
    },
    {
        "src_smiles": "CN1CCN(c2ncc3nc(CCc4ccccc4)c(=O)n(C)c3n2)CC1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, CN1CCN(c2ncc3nc(CCc4ccccc4)c(=O)n(C)c3n2)CC1, consists of a piperazine ring (N1CCNCC1) connected to a fused heterocyclic system containing pyrazole and triazole rings. It features a benzyl substituent attached to the triazole ring, and a methyl group linked to the carbonyl moiety.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity due to the presence of nitrogen-rich heterocycles capable of forming hydrogen bonds with the kinase's active site. The benzyl group may contribute to hydrophobic interactions, enhancing binding affinity.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal hydrogen bond donors/acceptors and hydrophobic regions needed for maximal interaction with GSK3-beta. Additionally, the molecule's flexibility might reduce binding specificity and affinity.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond acceptors to strengthen interactions with the kinase's active site. Incorporate a rigid aromatic core to enhance \u03c0-\u03c0 stacking interactions and reduce molecular flexibility, thereby increasing binding specificity and affinity. Modify the benzyl group to include electron-withdrawing substituents to improve binding through enhanced hydrophobic interactions.",
            "Final Target Molecule": "CN1CCN(c2ncc3nc(CCc4c(F)cccc4)c(=O)n(C)c3n2)CC1"
        }
    },
    {
        "src_smiles": "CCC(C)(C)Nc1c(C#N)cnc2cnc(NCc3cccnc3)cc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a tert-butyl amine moiety connected to a fused bicyclic system comprising pyrimidine and pyrazine rings. It includes a nitrile group and a triazole ring, which may contribute to its interaction with the GSK3-beta active site. The molecule is moderately bulky due to the tert-butyl group, which could influence its binding affinity and selectivity.",
            "Property Analysis": "The molecule exhibits inhibitory activity against GSK3-beta, potentially through hydrogen bonding and hydrophobic interactions within the kinase's active site. However, the current potency may be limited, and selectivity over other kinases could be suboptimal, affecting its therapeutic potential.",
            "Limitation in Source Molecule for Property": "The bulky tert-butyl group may hinder optimal binding interactions, reducing potency and selectivity. Additionally, the presence of multiple nitrogen atoms could lead to off-target interactions, decreasing the molecule's specificity for GSK3-beta.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, replace the bulky tert-butyl group with a less sterically hindered substituent to improve binding flexibility. Introduce additional hydrogen bond donors or acceptors to strengthen interactions with key amino acid residues in the active site. Modify the heterocyclic core to increase selectivity by reducing off-target kinase interactions, potentially by adding substituents that complement the unique pockets of GSK3-beta.",
            "Final Target Molecule": "CCNC1=CC(C#N)=NC2=CC=CC(NC3=CC=CC=N3)=C12"
        }
    },
    {
        "src_smiles": "CC(C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central acetylated amine linked to a thiophene ring and a phenyl ring. It contains a bulky tert-butyl group and a hydroxyl-substituted thiophene moiety, which may contribute to hydrophobic interactions and potential binding affinity towards GSK3-beta.",
            "Property Analysis": "The molecule demonstrates potential GSK3-beta inhibitory activity through its ability to form hydrogen bonds and hydrophobic interactions within the enzyme's active site. The presence of multiple aromatic rings may enhance \u03c0-\u03c0 stacking interactions, while the hydroxyl group can act as a hydrogen bond donor or acceptor.",
            "Limitation in Source Molecule for Property": "The bulky tert-butyl group may introduce steric hindrance, potentially reducing binding affinity and selectivity. Additionally, the molecule may lack sufficient hydrogen bond donors/acceptors to optimize interactions with key residues in the GSK3-beta active site, potentially limiting its inhibitory potency.",
            "Optimization for Source Molecule": "Modify the bulky tert-butyl group to a less sterically hindering substituent, such as an isopropyl or methyl group, to enhance binding affinity and selectivity. Introduce additional hydrogen bond donors or acceptors by adding hydroxyl or amino groups to strengthen interactions with GSK3-beta. Optimize the thiophene substitution to improve electronic properties and binding interactions.",
            "Final Target Molecule": "CC(C(=O)Nc1ncc(SC(C)C2ncc(C(C)C)o2)s1)c1ccccc1)"
        }
    },
    {
        "src_smiles": "CC(C)n1cnc2c(NCc3ccccc3)nc(I)nc21",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule, CC(C)n1cnc2c(NCc3ccccc3)nc(I)nc21, features an isopropyl-substituted triazolopyridazine core fused with a benzylamine moiety and an iodine atom. The bicyclic heteroaromatic structure provides rigidity and potential binding sites for kinase interaction.",
            "Property Analysis": "The molecule exhibits structural features conducive to GSK3-beta inhibition, including the heteroaromatic core which can engage in hydrogen bonding and hydrophobic interactions. The iodine atom may enhance binding affinity through halogen bonding, while the benzylamine moiety offers additional points for interaction.",
            "Limitation in Source Molecule for Property": "The iodine substituent may increase molecular size and lipophilicity excessively, potentially leading to poor solubility and unfavorable pharmacokinetic properties. Additionally, the isopropyl group may introduce steric hindrance, reducing optimal binding orientation and affinity towards GSK3-beta.",
            "Optimization for Source Molecule": "Replace the iodine atom with a smaller halogen such as fluorine to reduce steric bulk and improve solubility. Modify the isopropyl group to a methyl group to decrease lipophilicity and enhance binding flexibility. Introduce a hydroxyl or amine functional group to increase hydrogen bonding capacity, thereby improving interactions with the GSK3-beta active site.",
            "Final Target Molecule": "CC(C)N1CNC2C(NCc3ccccc3)NC(F)NC21"
        }
    },
    {
        "src_smiles": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a thioether-linked piperazine core fused to a bicyclic system containing nitrogen atoms. It features an ethoxycarbonylamide side chain attached to a phenyl ring, which may interact with the GSK3-beta binding site through hydrogen bonding and hydrophobic interactions.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta), an enzyme involved in various cellular processes including cell division and metabolism. Effective inhibition of GSK3-beta is of interest for therapeutic applications in diseases such as Alzheimer's and diabetes.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding affinity and selectivity towards GSK3-beta due to limited interaction points within the active site. Additionally, the presence of the thioether linkage could be susceptible to metabolic degradation, potentially reducing the compound's stability and bioavailability.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce electron-withdrawing substituents on the phenyl ring to strengthen binding interactions within the kinase pocket. Replace the thioether linkage with a more metabolically stable bioisostere, such as a sulfone or amide, to improve the compound's stability and pharmacokinetic profile. Additionally, modify the ethoxycarbonylamide side chain to enhance hydrogen bonding with key residues in the active site.",
            "Final Target Molecule": "COCCSO2c1n[nH]c2cc(NC(=O)NC(C)c3c(F)cccc3)ncc12"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCOCC3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central piperazine ring fused with a triazole moiety, connected to a phenyl group. It incorporates a carbamate linker attached to an ether-linked cyclohexane ring, contributing to its overall structural complexity and potential binding interactions.",
            "Property Analysis": "The molecule acts as an inhibitor of Glycogen Synthase Kinase 3-beta (GSK3-beta) with moderate potency. Its balanced hydrophobic and hydrophilic regions facilitate effective binding to the kinase's active site while maintaining favorable bioavailability.",
            "Limitation in Source Molecule for Property": "The source molecule may suffer from limited selectivity against other kinases due to its structural similarity to generic kinase inhibitors. Additionally, the ether-linked cyclohexane may be prone to metabolic instability, potentially leading to rapid clearance and reduced efficacy.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introduce electron-withdrawing groups on the phenyl ring to improve binding affinity and selectivity. Replace the ether linkage with a more metabolically stable moiety, such as a fluorinated group, to increase metabolic stability and prolong the compound's half-life.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCC(F)C)c2cn1)c1ccccc1"
        }
    },
    {
        "src_smiles": "CC(=O)c1ccc(-c2cccc(COC3COc4nc([N+](=O)[O-])cn4C3)c2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features an acetophenone core with a para-substituted phenyl ring. Attached to this phenyl ring is a naphthalene moiety connected via an ether linkage (COC). The naphthalene ring is further substituted with a cyclic imidazole containing a nitro group, which may influence the molecule's electronic properties and binding interactions.",
            "Property Analysis": "The molecule exhibits potential for GSK3-beta inhibition due to its extended aromatic systems and the presence of heteroatoms, which can facilitate strong interactions with the kinase's active site. The nitro group may contribute to binding affinity through hydrogen bonding and electronic effects, enhancing the overall inhibitory activity.",
            "Limitation in Source Molecule for Property": "The nitro group present on the cyclic imidazole may reduce the molecule's metabolic stability and increase toxicity. Additionally, the rigid aromatic systems could limit the molecule's flexibility, potentially hindering optimal binding conformation with GSK3-beta. Solubility issues may also arise due to the extensive aromaticity and nitro functionalities.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, the nitro group can be replaced with a more metabolically stable amine group to enhance safety and bioavailability. Introducing subtle substituents on the aromatic rings could increase binding affinity and selectivity. Enhancing molecular flexibility by modifying the ether linkage may allow better accommodation within the kinase binding pocket. Additionally, adding polar functional groups could improve solubility without compromising activity.",
            "Final Target Molecule": "CC(=O)c1ccc(-c2cccc(COC3COc4nc(CN4C3))c2)cc1"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1 comprises a benzamide core linked to a substituted pyrazole moiety. The presence of a trifluoromethyl group (CNCC(F)(F)F) introduces electron-withdrawing characteristics, potentially enhancing binding affinity. The molecule contains multiple nitrogen atoms, which can participate in hydrogen bonding, potentially improving interactions with the GSK3-beta active site.",
            "Property Analysis": "The compound exhibits inhibitory activity against GSK3-beta, likely due to its ability to engage with key amino acid residues within the kinase's active site. The trifluoromethyl group may contribute to binding through hydrophobic interactions and electron-withdrawing effects, potentially stabilizing the inhibitor-enzyme complex.",
            "Limitation in Source Molecule for Property": "The bulky trifluoromethyl group may cause steric hindrance, potentially limiting optimal binding orientations. Additionally, the current molecular scaffold may lack sufficient selectivity, increasing the risk of off-target effects. The molecule might also possess suboptimal pharmacokinetic properties, such as poor solubility or metabolic instability, which can hinder its therapeutic effectiveness.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications should focus on reducing steric hindrance and increasing selectivity. Replacing the trifluoromethyl group with a smaller electron-withdrawing moiety could improve binding orientation. Introducing polar functional groups may enhance solubility and metabolic stability. Structural analogs with varying linker lengths between the benzamide and pyrazole cores should be synthesized to optimize spatial interactions within the active site. Additionally, incorporating substituents that enhance hydrogen bonding could improve binding affinity and selectivity.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(O)H)c2cn1)c1ccccc1"
        }
    },
    {
        "src_smiles": "Cc1ccccc1-c1ccc(CC2NC(=O)c3cc(Cl)ccc3N(C)C2=O)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a toluene moiety connected to a biphenyl system. The biphenyl is substituted with a linker containing a cyclic urea moiety fused to a chloro-substituted aromatic ring. Key structural features include two aromatic rings providing hydrophobic interactions, amide linkages that can serve as hydrogen bond acceptors, and a chlorine atom which may contribute to binding affinity through halogen bonding or hydrophobic interactions.",
            "Property Analysis": "GSK3-beta inhibitors typically require interactions with key residues in the kinase active site, often involving hydrogen bonding, hydrophobic interactions, and sometimes halogen bonding. The presence of aromatic rings in the source molecule can facilitate \u03c0-\u03c0 stacking interactions, while the amide linkages can form hydrogen bonds with the kinase. The chloro substituent may enhance binding affinity through additional hydrophobic or halogen bonding interactions.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal positioning of hydrogen bond donors/acceptors necessary for maximal interaction with GSK3-beta active site residues. Additionally, the flexibility introduced by the linker might reduce binding specificity and affinity. The chloro substituent, while beneficial, might not be optimally oriented for halogen bonding interactions required for potent inhibition.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibitory activity, introduce a hydroxyl group to the aromatic ring to serve as an additional hydrogen bond acceptor/donor, improving interactions with the kinase. Modify the linker to reduce flexibility, possibly by introducing a rigid spacer to position the aromatic rings for better alignment within the active site. Replace the chlorine atom with a fluorine to favor halogen bonding with specific residues in GSK3-beta, potentially increasing binding affinity and selectivity.",
            "Final Target Molecule": "Cc1cc(O)c(Cc2ccccc2)-c3ccc(CC4N(C(=O)OC(C)C4)c5cc(Cl)c(=O)n5)cc3"
        }
    },
    {
        "src_smiles": "COCC(O)CNC(=O)c1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of an ether-linked alcohol group (COCC(O)), a carbamate moiety (CNC(=O)), and a fused bicyclic system containing a triazole ring and an aromatic ring. Additionally, it features a secondary carbamate linked to a cyclohexyl group and a phenyl ring, providing multiple sites for potential interactions.",
            "Property Analysis": "GSK3-beta inhibitors typically require specific hydrogen bond donors and acceptors, along with hydrophobic regions to interact effectively within the kinase's ATP-binding pocket. The molecule's aromatic systems facilitate hydrophobic interactions, while the carbamate groups can form hydrogen bonds, contributing to binding affinity and selectivity.",
            "Limitation in Source Molecule for Property": "The molecule may suffer from excessive flexibility due to the ether linkage, potentially reducing binding specificity and affinity. Additionally, the presence of multiple hydrogen bond donors could lead to off-target interactions and decrease membrane permeability, limiting its effectiveness as a GSK3-beta inhibitor.",
            "Optimization for Source Molecule": "Introduce rigid aromatic frameworks to reduce molecular flexibility and enhance binding specificity. Replace the flexible ether linkage with a more rigid linker to improve conformational stability. Add halogen substituents on the aromatic rings to increase hydrophobic interactions within the GSK3-beta active site. Reduce the number of hydrogen bond donors to enhance selectivity and membrane permeability.",
            "Final Target Molecule": "COC(C)cNC(=O)c1n[nH]c2c(C)c(NC(=O)NC(C)c3ccc(F)cc3)cc12"
        }
    },
    {
        "src_smiles": "CNc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central pyrazole core substituted with multiple aromatic rings. It includes a triazole moiety connected to a phenyl ring that bears a trifluoromethyl group and an amide linkage to another aromatic ring. Additional substitutions include methoxy groups and methyl groups, contributing to the molecule's overall hydrophobicity and potential for hydrogen bonding interactions.",
            "Property Analysis": "The molecule exhibits inhibitory activity against GSK3-beta, likely due to its ability to engage in hydrogen bonding and hydrophobic interactions within the kinase's active site. The presence of fluorinated groups may enhance metabolic stability and membrane permeability, while the amide linkage could facilitate specific binding interactions.",
            "Limitation in Source Molecule for Property": "The current structure may have limited selectivity towards GSK3-beta due to its broad hydrophobic profile and lack of specific interactions that could enhance binding affinity. Additionally, the molecule may possess suboptimal solubility and pharmacokinetic properties, potentially affecting its bioavailability and efficacy.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications should aim to increase binding affinity and selectivity. Introducing additional polar functional groups could improve hydrogen bonding capabilities, while refining the hydrophobic regions may enhance specificity. Incorporating substituents that exploit unique binding pockets of GSK3-beta can improve selectivity. Additionally, optimizing the molecule's solubility through the introduction of polar or ionizable groups may enhance pharmacokinetic properties.",
            "Final Target Molecule": "CNc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1CC(O)C"
        }
    },
    {
        "src_smiles": "CCOC(=O)C1(C(=O)NC(Cc2ccc(-c3ccccc3OC)cc2)C(=O)O)CCCO1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule comprises an ethyl ester linked to a bicyclic ring system containing amide and carbonyl functionalities. It features a substituted aromatic ring with a methoxy group at the para position, enhancing its electron-donating properties. The molecule also contains a flexible alkyl chain that may influence its binding interactions.",
            "Property Analysis": "The molecule exhibits moderate inhibition of GSK3-beta, likely through interactions within the ATP-binding site. Key functional groups contributing to activity include the amide linkage and the methoxy-substituted aromatic ring, which facilitate hydrogen bonding and hydrophobic interactions with the kinase.",
            "Limitation in Source Molecule for Property": "The current structure may lack optimal interactions for maximal inhibition of GSK3-beta. Specifically, the molecule may benefit from additional hydrogen bond donors or acceptors to enhance binding affinity. The flexible alkyl chain might also reduce binding specificity and affinity due to entropic penalties.",
            "Optimization for Source Molecule": "Introduce electron-withdrawing groups to the aromatic ring to strengthen interactions with the kinase. Modify the ester linker to a more rigid amide or sulfonamide to reduce conformational flexibility and improve binding specificity. Add hydroxyl or amino substituents to provide additional hydrogen bonding opportunities, thereby enhancing inhibitory potency against GSK3-beta.",
            "Final Target Molecule": "CC(=O)NC1(C(=O)NC(Cc2ccc(-c3ccccc3OC(=O)O)cc2)C(=O)O)CCCO1"
        }
    },
    {
        "src_smiles": "CC(C)CC(NC(c1ccc(-c2ccc(C#N)cc2)cc1)C(F)(F)F)C(=O)NCC#N",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a propane backbone with a branching at the second carbon (CC(C)CC). It contains an amide linkage connecting to a nitrogen atom bonded to a trifluoromethyl-substituted aromatic ring (C(F)(F)F) and a nitrile group (C#N). Additionally, there is an extended nitrile-containing side chain (NCC#N) connected via another amide group. The molecule incorporates multiple functional groups, including amides, nitriles, and trifluoromethyl groups, which contribute to its chemical stability and potential biological activity.",
            "Property Analysis": "The molecule is designed to inhibit Glycogen Synthase Kinase 3-beta (GSK3-beta), an enzyme implicated in various diseases including Alzheimer's, diabetes, and cancer. The presence of electron-withdrawing groups like trifluoromethyl and nitrile may enhance binding affinity to the kinase's active site by stabilizing interactions through hydrogen bonding and dipole interactions. The overall structure suggests potential for high specificity and potency against GSK3-beta.",
            "Limitation in Source Molecule for Property": "Despite the potential strong binding affinity, the presence of multiple nitrile groups may adversely affect the molecule's solubility and bioavailability. Additionally, the rigid aromatic system with electron-withdrawing groups might limit the molecule's flexibility, potentially reducing its ability to adapt to different conformations required for optimal binding. There may also be concerns regarding metabolic stability and potential off-target interactions due to the trifluoromethyl group.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, introduce structural modifications that enhance solubility and reduce metabolic liabilities. Substituting one of the nitrile groups with a bioisostere such as a cyano group can maintain electronic properties while improving pharmacokinetic profiles. Incorporating a heteroaryl ring may increase binding interactions through additional hydrogen bonding or hydrophobic contacts. Additionally, modifying the trifluoromethyl group to a less lipophilic substituent could enhance solubility and reduce off-target effects.",
            "Final Target Molecule": "CC(C)CC(NC(c1ccn(c2ccc(C(F)(F)F)cc2)cc1)C(F)(F)F)C(=O)NCC#N)"
        }
    },
    {
        "src_smiles": "Cc1c(F)ccc(C(=O)Nc2cc(C(=O)O)ccc2N2CCN(C)CC2)c1Cl",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a fluorinated aromatic ring substituted with a chloro group, connected via an amide linker to a piperazine ring that is further attached to a carboxylic acid-substituted aromatic ring. Key functional groups include the amide, tertiary amine, and halogen substituents, which contribute to its overall molecular framework.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta) through interactions facilitated by its aromatic rings and hydrogen bond donors/acceptors. The presence of electron-withdrawing halogen atoms may enhance binding affinity by stabilizing key interactions within the kinase active site.",
            "Limitation in Source Molecule for Property": "The bulkiness of the chloro and fluoro substituents may hinder optimal binding orientation within the GSK3-beta active site, potentially reducing potency. Additionally, the amide linkage may be susceptible to metabolic hydrolysis, affecting the molecule's stability and bioavailability.",
            "Optimization for Source Molecule": "Modify the aromatic substituents to reduce steric hindrance, possibly replacing chlorine with a smaller substituent to enhance binding flexibility. Substitute the amide linker with a more metabolically stable bioisostere, such as a urea or sulfonamide group, to improve the molecule's stability and prolong its inhibitory effect on GSK3-beta.",
            "Final Target Molecule": "Cc1c(F)ccc(C(=O)N(C(=O)N)Cc2cc(C(=O)O)ccc2N2CCN(C)CC2)c1Cl"
        }
    },
    {
        "src_smiles": "CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule contains a central piperazine ring substituted with a propyl chain linked to a triazole-fused quinoxaline core. Substituents include two chlorine atoms on the phenyl ring and a dimethylamino group attached to the triazole. The molecule features multiple nitrogen atoms which may contribute to hydrogen bonding and overall binding affinity.",
            "Property Analysis": "The molecule exhibits potential GSK3-beta inhibitory activity through interactions of its nitrogen-containing rings with the kinase active site. The presence of electron-withdrawing chlorine atoms may enhance binding through hydrophobic interactions and possible hydrogen bond acceptors.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from suboptimal binding affinity due to limited hydrogen bonding donors, possible conformational rigidity reducing fit into the active site, and insufficient interactions to enhance selectivity and potency against GSK3-beta.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors to strengthen interactions with the kinase active site. Modify the triazole ring to increase flexibility, allowing better conformational adaptation. Replace one chlorine atom with a methoxy group to enhance solubility and provide a hydrogen bond donor site. Optimize the substituents on the quinoxaline core to improve binding specificity and potency.",
            "Final Target Molecule": "CN1CCN(CCCOc2ncc3cc(-c4c(Cl)cccc4OC)c(=O)n(C)c3n2)CC1"
        }
    },
    {
        "src_smiles": "COc1cccc(Cl)c1-c1ccc(COC2COc3nc([N+](=O)[O-])cn3C2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule comprises a methoxy-substituted phenyl ring (COc1cccc(Cl)c1) connected via a single bond to another phenyl ring substituted with a diaryl ether linkage. This linkage connects to a cyclic structure featuring an ether bridge (COC2CO) and a triazole-like ring containing a nitro group (nc([N+](=O)[O-])cn3C2). The molecule displays multiple aromatic systems, ether linkages, and a nitro-substituted nitrogen-containing heterocycle.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta), which is implicated in various cellular processes including metabolism, cell cycle regulation, and neurodegenerative diseases. The presence of electron-withdrawing groups and nitrogen heterocycles likely contributes to its binding affinity and inhibitory potency towards GSK3-beta.",
            "Limitation in Source Molecule for Property": "The source molecule may have limitations such as reduced selectivity for GSK3-beta due to the presence of multiple aromatic rings and potentially unfavorable pharmacokinetic properties like poor metabolic stability and bioavailability. Additionally, the nitro group may pose toxicity concerns and hinder optimal interaction with the target enzyme.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the nitro group can be replaced with a less toxic and more metabolically stable substituent such as a trifluoromethyl group. Reducing the number of ether linkages and optimizing the aromatic system can improve selectivity and binding affinity. Introducing electron-withdrawing groups may further enhance the inhibitory activity while maintaining favorable pharmacokinetic properties.",
            "Final Target Molecule": "COc1cccc(Cl)c1-c1ccc(COC2C(c3nc(C(F)(F)F)cn3)C2)cc1)"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)N3CC(=O)N(C)C3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central pyrazolo[1,5-a]pyrimidine core connected to an aniline moiety through an amide linkage. It includes multiple aromatic rings enhancing its planar structure, a piperazine ring which may contribute to solubility, and a methyl group attached to the amine, potentially influencing binding interactions.",
            "Property Analysis": "The molecule demonstrates potential as a GSK3-beta inhibitor due to its planar heterocyclic core which can engage in hydrogen bonding and \u03c0-\u03c0 interactions within the kinase's active site. The presence of amide linkages provides hydrogen bond donors and acceptors essential for binding affinity, while the piperazine ring may aid in improving pharmacokinetic properties.",
            "Limitation in Source Molecule for Property": "The source molecule may exhibit limited selectivity towards GSK3-beta due to its extended aromatic system, increasing the risk of off-target interactions with other kinases. Additionally, the molecule's hydrophobic nature could lead to poor solubility and bioavailability. The amide bonds may also be susceptible to metabolic hydrolysis, potentially reducing the molecule's stability in vivo.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, introducing electron-withdrawing groups on the aromatic rings could increase binding affinity by strengthening hydrogen bonds. Modifying the piperazine ring to include additional polar substituents may improve solubility and selectivity. Replacing the amide linkage with a more metabolically stable alternative, such as a sulfonamide or a triazole linker, can enhance the molecule's stability. Incorporating a chlorine substituent could also improve binding specificity and potency.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)N3CNC(=O)N(C)(C)C3)c2cn1)c1ccc(cc1)Cl"
        }
    },
    {
        "src_smiles": "COc1ccc(NC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a methoxy-substituted phenyl ring connected via an amide linker to a fused triazole core. It incorporates chloro and additional methoxy groups on the triazole-containing aromatic rings, which contribute to its overall aromaticity and potential interactions with the GSK3-beta active site through hydrophobic and hydrogen-bonding interactions.",
            "Property Analysis": "The molecule demonstrates moderate inhibition of GSK3-beta, likely due to its ability to engage in key interactions within the kinase's active site. The presence of electron-donating methoxy groups may enhance binding affinity through favorable electronic interactions, while the chloro substituent contributes to hydrophobic binding pockets.",
            "Limitation in Source Molecule for Property": "The current structure may lack sufficient hydrogen bond donors to form stronger interactions with the kinase, potentially limiting binding affinity. Additionally, the rigidity introduced by the fused triazole core may restrict the molecule's conformational adaptability, preventing optimal fit within the active site.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond acceptor groups, such as hydroxyl or amino substituents, to enhance hydrogen bonding with the kinase. Modify the amide linker to incorporate a flexible side chain, allowing better conformational adaptability within the binding pocket. Replace one of the methoxy groups with a fluorine atom to increase electronic interactions and potentially improve metabolic stability.",
            "Final Target Molecule": "COc1ccc(NC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OF)cc23)cc1"
        }
    },
    {
        "src_smiles": "COc1ccccc1N(C)c1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a methoxyphenyl group, a diphenylpyridine core, and a morpholinoethyl substituent linked via amide bonds. It contains multiple hydrogen bond donors and acceptors, aromatic rings for \u03c0-\u03c0 interactions, and a basic nitrogen in the morpholine ring.",
            "Property Analysis": "The molecule demonstrates moderate inhibition of GSK3-beta, with potential for good binding affinity due to hydrogen bonding and hydrophobic interactions. However, its solubility and selectivity may need improvement to enhance its pharmacokinetic and pharmacodynamic profiles.",
            "Limitation in Source Molecule for Property": "The presence of multiple hydrogen bond donors may lead to poor membrane permeability and metabolic instability. Additionally, the morpholinoethyl group might contribute to off-target effects, reducing selectivity towards GSK3-beta.",
            "Optimization for Source Molecule": "Introduce bioisosteric replacements to reduce the number of hydrogen bond donors, such as replacing the morpholine ring with a less polar heterocycle. Enhance lipophilicity by adding fluorine atoms or aromatic substitutions to improve membrane permeability and binding affinity. Modify the amide linkage to improve metabolic stability and selectivity.",
            "Final Target Molecule": "COc1ccccc1N(C)c1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CC(F)CC2)cc1"
        }
    },
    {
        "src_smiles": "O=C(NC(Cc1ccc(O)cc1)C(=O)NCC1CC(Br)=NO1)OCc1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of an amide linkage connecting a phenyl ether moiety to a complex fused heterocyclic system. It includes multiple aromatic rings, a bromine-substituted piperazine ring, and an oxime functional group. The molecule exhibits potential hydrogen bond donors and acceptors, as well as halogen bonding capabilities, which may facilitate interactions with the GSK3-beta active site.",
            "Property Analysis": "The molecule has a balanced combination of hydrophobic and hydrophilic regions, which is favorable for cell permeability and binding affinity to GSK3-beta. The presence of aromatic rings allows for \u03c0-\u03c0 stacking interactions, while the bromine atom can engage in halogen bonding. The oxime group may contribute to binding through hydrogen bonding.",
            "Limitation in Source Molecule for Property": "The oxime moiety may introduce metabolic instability and increase polarity, potentially reducing cell permeability. Additionally, the bromine substitution could lead to off-target interactions and affect the selectivity of GSK3-beta inhibition. The overall molecular weight and lipophilicity might also limit optimal drug-like properties.",
            "Optimization for Source Molecule": "Replace the oxime group with a more metabolically stable amide or ether linkage to enhance stability. Substitute the bromine atom with a less bulky halogen, such as fluorine, to improve selectivity and reduce potential off-target effects. Introduce polar functional groups to balance lipophilicity and maintain cell permeability. Optimize the aromatic regions to enhance \u03c0-\u03c0 interactions specifically with GSK3-beta.",
            "Final Target Molecule": "O=C(NC(Cc1ccc(O)cc1)C(=O)NCC1CC(F)=NO1)OCc1ccccc1"
        }
    },
    {
        "src_smiles": "Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-c2cnn(C)c2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of multiple aromatic rings, including a substituted benzamide moiety and a triazole-containing ring system. It features a nitro functional group, a carboxylic acid, and a nitrile group, which contribute to its overall polarity and potential binding interactions with GSK3-beta.",
            "Property Analysis": "The molecule exhibits inhibitory activity against Glycogen Synthase Kinase 3-beta (GSK3-beta), likely through hydrogen bonding and hydrophobic interactions within the ATP-binding pocket of the enzyme. The presence of electron-withdrawing groups enhances binding affinity by stabilizing the interaction with key amino acid residues.",
            "Limitation in Source Molecule for Property": "The nitro group may pose metabolic stability and toxicity issues, potentially limiting the compound's drug-likeness. Additionally, the carboxylic acid group could reduce cell permeability, hindering effective intracellular inhibition of GSK3-beta.",
            "Optimization for Source Molecule": "Replace the nitro group with a bioisostere such as a cyano or trifluoromethyl group to improve metabolic stability and reduce toxicity. Modify the carboxylic acid to a methyl ester to enhance cell permeability while maintaining necessary binding interactions. Introduce fluorine atoms on the aromatic rings to increase binding affinity and metabolic resistance.",
            "Final Target Molecule": "Cc1cc(C(CN)ccc1)-n1c(CCC(=O)O)ccc1-c1ccc(-c2cc(F)nc(C)c2)cc1"
        }
    },
    {
        "src_smiles": "CN1C(=O)C(Cc2ccc(-c3ccccc3[N+](=O)[O-])cc2)NC(=O)c2cc(Cl)ccc21",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central pyrimidine ring connected to various functional groups, including a carbamate linkage, a biphenyl moiety substituted with a nitrobenzene sulfonamide, and a chlorophenyl group. This structure allows for multiple points of interaction, such as hydrogen bonding and hydrophobic interactions, which are essential for kinase inhibition.",
            "Property Analysis": "The molecule demonstrates potential GSK3-beta inhibition through interactions within the kinase active site, leveraging hydrogen bond donors/acceptors and hydrophobic regions. The presence of electron-withdrawing groups like nitro and chloro may enhance binding affinity but could also impact selectivity and metabolic stability.",
            "Limitation in Source Molecule for Property": "The nitro group may contribute to undesirable off-target effects and reduced metabolic stability. Additionally, the existing substitutions might not fully exploit all binding interactions within the GSK3-beta active site, potentially limiting the inhibitory potency and selectivity.",
            "Optimization for Source Molecule": "Replace the nitrobenzene moiety with a more metabolically stable and selective heterocyclic aromatic group, such as a pyridine or pyrazole derivative. Introduce additional substituents to enhance hydrogen bonding and hydrophobic interactions within the kinase active site. Optimize the chlorophenyl group to improve binding affinity and selectivity, possibly by varying the position or substituting with other halogens.",
            "Final Target Molecule": "CN1C(=O)C(Cc2ccc(-c3c(ncc3)N)cc2)NC(=O)c2cc(Cl)ccc21"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)NCC(O)C(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features an amide-linked urea moiety connected to a fused heterocyclic system containing a pyrimidinedione core. It includes aromatic rings and a fluorinated alcohol side chain, providing multiple points for hydrogen bonding and hydrophobic interactions, which are crucial for binding to GSK3-beta.",
            "Property Analysis": "The molecule shows potential as a GSK3-beta inhibitor with moderate binding affinity. The fluorinated alcohol may enhance metabolic stability and membrane permeability. However, the compound may exhibit limited selectivity and suboptimal solubility, which could affect its efficacy and pharmacokinetic profile.",
            "Limitation in Source Molecule for Property": "The source molecule may have inadequate binding interactions within the ATP-binding pocket of GSK3-beta, leading to lower inhibition potency. Additionally, high lipophilicity could reduce solubility and increase off-target effects, while the existing functional groups may limit further optimization opportunities for enhancing selectivity and potency.",
            "Optimization for Source Molecule": "Introduce polar functional groups to improve solubility and hydrogen bonding capabilities. Modify the aromatic system to enhance specific interactions within the GSK3-beta active site, potentially increasing binding affinity and selectivity. Reduce lipophilicity by altering or removing non-essential hydrophobic groups to improve pharmacokinetic properties. Optimize the linker region to better fit the spatial requirements of the binding pocket.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2ncnn(C(=O)NCC(O)C(F)F)c2n1)c1ccccc1O"
        }
    },
    {
        "src_smiles": "CCCCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of a hexylamino group attached to a fused heterocyclic system containing pyrimidine and triazine rings. It features two para-substituted dichlorophenyl groups connected through a carbonyl-linked nitrogen atom, enhancing its aromatic character and potential for hydrogen bonding.",
            "Property Analysis": "GSK3-beta inhibitors typically require specific interactions within the ATP-binding site of the kinase, including hydrogen bonding and hydrophobic interactions. The presence of dichlorophenyl groups offers hydrophobic interactions, while the carbonyl and amino functionalities can participate in hydrogen bonding, both critical for effective inhibition.",
            "Limitation in Source Molecule for Property": "The current molecule may exhibit limited selectivity and potency due to the lack of specific interactions required for optimal binding affinity to GSK3-beta. Additionally, the flexible hexyl chain might reduce binding specificity and increase off-target effects.",
            "Optimization for Source Molecule": "Introduce rigidified aromatic systems to enhance binding specificity and affinity. Replace the flexible hexyl chain with a more constrained linker to position the dichlorophenyl groups optimally within the active site. Incorporate additional hydrogen bond donors or acceptors to form stronger interactions with key residues in GSK3-beta. Modify the substitution pattern on the phenyl rings to improve electronic properties and enhance hydrophobic interactions.",
            "Final Target Molecule": "CCCCCOc1ncc2cc(-c3c(Cl)ccccc3Cl)c(=O)n(C)c2n1"
        }
    },
    {
        "src_smiles": "CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(Oc2ccccc2O)n1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule consists of an ethoxy chain connected to a bicyclic scaffold containing a fluorophenyl group and two methoxyphenyl substituents. The core structure includes a heterocyclic system with oxygen and nitrogen atoms, which may contribute to its binding interactions with GSK3-beta. The molecule's multiple aromatic rings and functional groups provide potential sites for hydrogen bonding and hydrophobic interactions, which are crucial for enzyme inhibition.",
            "Property Analysis": "The source molecule exhibits inhibitory activity against GSK3-beta, potentially through interactions between its heterocyclic core and the kinase's active site. The presence of electron-withdrawing fluorine and electron-donating methoxy groups may influence its binding affinity and selectivity. Its solubility and permeability are balanced by the ethoxy chain and polar functional groups, contributing to its pharmacokinetic properties.",
            "Limitation in Source Molecule for Property": "While the source molecule shows GSK3-beta inhibition, its potency may be limited by suboptimal binding interactions within the enzyme's active site. The presence of multiple aromatic rings could lead to increased lipophilicity, potentially affecting solubility and selectivity. Additionally, the molecule may have metabolic liabilities due to the ether and methoxy groups, impacting its stability and bioavailability.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, modifications can be made to increase binding affinity and selectivity. Introducing additional hydrogen bond donors or acceptors could improve interactions with the kinase's active site. Reducing lipophilicity by modifying or replacing some aromatic rings may enhance solubility and selectivity. Stabilizing the molecule against metabolic degradation by altering ether or methoxy groups could improve its pharmacokinetic profile. Structure-activity relationship (SAR) studies should guide the substitution patterns to optimize these properties.",
            "Final Target Molecule": "CCCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(Oc2ccccc2OCC)n1"
        }
    },
    {
        "src_smiles": "COc1cc(Cc2cnc(N)nc2N)ccc1OCc1ccc(-c2csnn2)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule features a central benzene ring substituted with two methoxy groups and a side chain containing a bicyclic structure with triazole and thiosemicarbazone functionalities. The presence of multiple nitrogen atoms in the triazole ring may facilitate hydrogen bonding and enhance binding interactions with biological targets.",
            "Property Analysis": "The molecule exhibits potential as a GSK3-beta inhibitor due to the planar aromatic system and the electron-rich triazole moiety, which can interact with the kinase's active site. The methoxy groups may enhance lipophilicity, potentially improving membrane permeability and bioavailability.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited selectivity towards GSK3-beta, possibly leading to off-target effects. Additionally, the presence of multiple methoxy groups could result in metabolic instability and rapid clearance from the body, reducing the compound's effectiveness.",
            "Optimization for Source Molecule": "Introduce substituents that increase selectivity for GSK3-beta by enhancing specific interactions within the kinase's binding pocket. Replace methoxy groups with more metabolically stable moieties such as fluorine or hydroxyl groups to improve metabolic stability. Modify the side chain to include rigidifying elements that could enhance binding affinity and reduce conformational flexibility.",
            "Final Target Molecule": "COc1cc(Cc2cnc(N)nc2N)ccc1OCc1ccc(-c2c(F)snn2)cc1"
        }
    },
    {
        "src_smiles": "COCCn1c(=O)c(-c2ccc(OC)cc2)nc2cnc(OCc3ccccc3)nc21",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a pyrimidine derivative featuring multiple methoxy-substituted phenyl rings connected via ethoxy linkers. It has a central pyrimidine core substituted with two 4-methoxyphenyl groups and an ethoxycarbonyl moiety, which may facilitate binding interactions with the GSK3-beta enzyme.",
            "Property Analysis": "The molecule exhibits inhibitory activity against GSK3-beta, likely through interactions within the ATP-binding site of the enzyme. The methoxy groups may contribute to hydrogen bonding and hydrophobic interactions, enhancing binding affinity and selectivity.",
            "Limitation in Source Molecule for Property": "The current structure may suffer from limited binding specificity and suboptimal interactions within the GSK3-beta active site. Additionally, the presence of multiple methoxy groups might reduce metabolic stability and increase polarity, potentially affecting bioavailability and cell permeability.",
            "Optimization for Source Molecule": "Introduce additional hydrogen bond donors or acceptors to enhance specific interactions with key residues in the GSK3-beta active site. Modify the methoxy groups to improve metabolic stability, such as by introducing fluorine atoms or replacing them with more metabolically stable substituents. Optimize the ethoxy linker to reduce polarity and enhance cell permeability, potentially by shortening the linker or introducing conformational constraints.",
            "Final Target Molecule": "COCClc1c(NC(=O)c2ccc(OC(F))cc2)nc3cnc(OCc4ccccc4)nc31"
        }
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCCOC(F)(F)F)c2cn1)c1ccc(F)cc1",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule comprises an amide linkage connecting an amino group to a pyrazolopyridine core. It features a difluorophenyl ring attached to the amide nitrogen and an ether-linked trifluoromethyl group, enhancing lipophilicity and potential metabolic stability. The molecule also includes a tetraethylene glycol-like spacer, which may influence solubility and binding interactions.",
            "Property Analysis": "The molecule demonstrates potential as a GSK3-beta inhibitor due to its pyrazolopyridine core, which is known to interact with the kinase active site. The presence of fluorine atoms can enhance binding affinity and metabolic stability. However, the high lipophilicity from the trifluoromethyl and ether groups may adversely affect aqueous solubility and bioavailability.",
            "Limitation in Source Molecule for Property": "Excessive lipophilicity may lead to poor solubility and unfavorable pharmacokinetic properties, such as limited bioavailability and increased nonspecific binding. Additionally, the current substituents may not provide optimal interactions for high selectivity and potency against GSK3-beta, potentially resulting in off-target effects.",
            "Optimization for Source Molecule": "To improve GSK3-beta inhibition, introduce polar functional groups to enhance solubility without significantly increasing molecular weight. Modify or reduce the length of the ether linker to decrease lipophilicity. Enhance the pyrazolopyridine core with substitutions that can form additional hydrogen bonds or pi-stacking interactions within the GSK3-beta active site to increase selectivity and binding affinity.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCCO)C2cn1)c1ccc(F)cc1"
        }
    },
    {
        "src_smiles": "Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(NCCCN3CCOCC3)nc21",
        "prop": "gsk",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a purine derivative featuring a methyl group attached to the nitrogen at position 1. It incorporates a 3,5-dichlorophenyl moiety and a piperazine-linked side chain. The structure contains multiple nitrogen atoms and chlorinated aromatic rings, which contribute to its potential biological activity by facilitating hydrogen bonding and hydrophobic interactions with target proteins.",
            "Property Analysis": "The molecule exhibits inhibition of Glycogen Synthase Kinase 3-beta (GSK3-beta), an enzyme involved in various cellular processes including metabolism, cell cycle regulation, and signaling pathways. Effective inhibition of GSK3-beta is of therapeutic interest in conditions such as Alzheimer's disease, diabetes, and certain cancers.",
            "Limitation in Source Molecule for Property": "The presence of multiple chlorinated aromatic rings may negatively impact the molecule's solubility and bioavailability. Additionally, the piperazine moiety could introduce metabolic instability and potential off-target effects. These structural features may limit the overall potency and selectivity of GSK3-beta inhibition.",
            "Optimization for Source Molecule": "To enhance GSK3-beta inhibition, the molecule can be optimized by reducing the number of chlorine substituents to improve solubility and reduce potential toxicity. Modifying the piperazine ring to a more metabolically stable linker, such as replacing it with a morpholine or azetidine ring, can enhance metabolic stability. Introducing electron-donating groups on the phenyl rings may improve binding affinity to the GSK3-beta active site. Additionally, optimizing the purine core to enhance specific interactions with key residues in the enzyme's binding pocket can increase potency and selectivity.",
            "Final Target Molecule": "Cn1c(=O)c(-c2ccccc2)cc2cnc(NCCCOCC3CCOCC3)nc21"
        }
    }
]